How membership-based integrative and functional medicine works — and whether it's right for you Written and medically reviewed by Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Based in San Antonio, Texas · Virtual practice serving TX, IA, IL, MO, FL, and GA www.directintegrativecare.com Last updated: August 2026 Medical Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, financial advice, tax advice, or a recommendation to discontinue health insurance coverage. Direct Care is not health insurance. Consult a qualified healthcare professional regarding your medical care and a qualified advisor regarding financial or tax decisions. What Is Direct Care, in One Paragraph? Direct Care is a membership model in which you pay your physician a flat monthly fee instead of routing every visit through insurance. That fee covers unhurried appointments, direct phone and text access, and ongoing care — with no copays and no billing surprises. It is not insurance, and it does not replace it: most members keep a high-deductible plan for hospitalization and emergencies. The trade is straightforward. Your physician carries a much smaller patient panel — roughly 400 patients in the average Direct Primary Care practice, versus 2,000 to 2,500 in a traditional one — and in exchange has the time to actually practice medicine. For integrative and functional medicine specifically, that time is not a luxury. It is the entire point. Root-cause work requires the kind of long, iterative conversations that a seven-minute insurance visit structurally cannot accommodate. Why Is Traditional Medicine So Rushed? The answer is billing, not indifference. In insurance-based practices, the office visit is the unit of transaction. Insurers pay for encounters. Phone consultations are generally not covered. Text messages to your doctor are not covered. A quick email that might save you an unnecessary appointment is not a billable event. This creates a perverse incentive. Every minute a physician spends answering your question by phone is a minute not generating revenue. The result is schedules packed with 20 to 30 or more patients per day, because that is what keeps the lights on and the staff paid. The math behind this is worse than most patients realize. Research published in the Journal of General Internal Medicine (Porter et al., 2022) estimated that a primary care physician would need 26.7 hours per day to deliver all guideline-recommended preventive, chronic, and acute care — plus documentation — for a standard panel of 2,500 patients. There are not that many hours in a day. Something has to give, and what gives is time with you. What Is Driving Patients and Physicians Toward This Model? Cost. The Kaiser Family Foundation's 2025 Employer Health Benefits Survey found that total annual premiums for employer-sponsored family coverage reached $26,993, with workers contributing an average of $6,850 from their paychecks. Mercer's 2025 survey projects health benefit costs per employee will rise 6.5% in 2026 — the steepest increase since 2010, and closer to 9% without employer cost-cutting. Many families now pay thousands out of pocket before a deductible is met. Physician burnout. The 2025 Commonwealth Fund International Health Policy Survey found that 43% of U.S. primary care physicians report burnout — the highest of ten developed countries surveyed. Among them, 44% cite administrative tasks as the primary driver and 65% say insurance-related paperwork is a major problem. A 2022 analysis in Mayo Clinic Proceedings estimated that burnout-related primary care turnover costs the system $260 million annually in excess healthcare spending. When the incentives punish both parties, people look for a different arrangement. How Does a Direct Care Membership Actually Work? In exchange for a flat monthly fee, members receive access that insurance-based practices structurally cannot offer: Unhurried appointments — 30 to 60 minutes, rather than the standard 5 to 10 Direct access — phone, text, email, and telemedicine, not just scheduled office visits Expanded availability — including evenings and weekends Smaller panels — the AAFP's 2024 DPC Data Brief puts the average Direct Primary Care panel at 402 patients Transparent pricing — one monthly fee, no copays, no surprise bills Your first appointment is typically an extended intake: full health history, current concerns, goals, and often lab work — the foundation for a personalized plan rather than a symptom-by-symptom triage. The model has scaled considerably. The DPC Coalition reports more than 2,300 DPC practices serving over 300,000 patients, while the DPC Frontier mapper now lists over 3,100 practice locations nationwide. Thirty-four states have passed laws defining DPC as a medical service rather than insurance. Why Is Direct Care a Natural Fit for Integrative and Functional Medicine? Because root-cause medicine is time-intensive, and insurance does not pay for time. Instead of prescribing something for each symptom and moving on, functional medicine asks why. Why is the blood pressure elevated? Why the persistent fatigue? What in your sleep, stress, nutrition, environment, or history is contributing? That detective work cannot be compressed into a rushed visit. Insurance reimbursement has always been poor for exactly these approaches: extended consultations, advanced functional testing, many integrative procedures. Supplements receive no coverage at all. For patients accustomed to paying à la carte every time a physician's time was involved, the membership model consolidates all of it into one predictable fee. This matters most for the conditions that don't fit neatly into conventional categories — autoimmune disease, chronic fatigue, fibromyalgia, MCAS, mold toxicity, long COVID, and the frustrating experience of being told "your labs are normal" while clearly not feeling well. These are precisely the cases that require time, sequencing, and iteration. In my own practice, I have capped my panel at 99 patients. That is smaller than the DPC average, and deliberately so. Complex, sensitive patients require a level of responsiveness that a larger panel cannot honestly support. What Does the Evidence Actually Show? Honestly: encouraging, but not definitive. A 2020 Society of Actuaries report prepared by Milliman found that patients enrolled in a DPC option used fewer downstream services, driven mainly by lower emergency department utilization — while also noting that an employer's net costs depend heavily on how the total benefits package is structured. Several employer-sponsored evaluations have reported reductions in ED visits and hospitalizations. The caveat matters: most of this evidence is observational and drawn from employer-sponsored populations, not randomized trials. Critics reasonably note that healthier patients may self-select into these practices. I think the model is sound and my patients do better under it, but I would rather tell you what the literature supports than oversell it. Is Direct Care Right for You? It tends to be a strong fit if you: Manage a chronic or complex condition requiring ongoing adjustment Have a high-deductible plan and are already paying out of pocket for primary care Want integrative or functional medicine and are tired of paying per visit Value access and continuity over having insurance process every transaction Have felt dismissed or rushed in conventional settings It may not be the right fit if you rarely use healthcare and are satisfied with your current arrangement, if a monthly fee on top of insurance premiums is not affordable, or if you need a physician who bills your insurance directly. Direct Care Is Not Insurance — This Part Matters Direct Care complements insurance; it does not replace it. Catastrophic coverage remains essential for hospitalization, surgery, cancer treatment, and serious accidents. Most members pair their membership with a high-deductible health plan, which typically carries a lower premium while protecting against major expenses. A note on Medicare. This is frequently misunderstood. Medicare beneficiaries can join most Direct Care practices. The complication sits on the physician's side: most DPC physicians formally opt out of Medicare, which means Medicare will not reimburse for that physician's services. Your Medicare coverage continues normally for everything else — hospitalizations, imaging, labs, specialists, and prescriptions. Medicare will not pay the membership fee itself. If you are on Medicare, ask any practice directly how they are structured before enrolling. Can I Use My HSA for a Direct Care Membership in 2026? Yes — this is new, and it is significant. Under the One Big Beautiful Bill Act (H.R. 1), signed July 4, 2025 and effective January 1, 2026, Direct Primary Care membership fees are recognized as qualified medical expenses under HSA rules. Pre-tax HSA funds may be used up to $150 per month for individuals and $300 per month for families. Just as importantly, a qualifying DPC arrangement no longer counts as disqualifying "other coverage," so pairing a membership with an HSA-eligible high-deductible plan no longer jeopardizes your ability to contribute. Consult your tax advisor about your specific situation. Summary: Direct Care at a Glance Traditional Insurance-Based Care Direct Care Membership Payment Fee-for-service billed to insurer Flat monthly fee paid to physician Typical panel size 2,000–2,500 patients ~400 patients (99 in my practice) Visit length 5–15 minutes 30–60 minutes Access between visits Limited; often not billable Phone, text, email, telemedicine Copays / surprise bills Common None for included services Functional medicine testing Spotty or no coverage Discussed openly; transparent pricing Replaces insurance? — No — pair with catastrophic/HDHP HSA-eligible (2026) — Yes, up to $150/mo individual, $300/mo family Frequently Asked Questions Is Direct Care the same as concierge medicine? No. Concierge practices typically still bill insurance and charge an additional retainer, often a substantially higher one. Direct Care practices generally do not bill insurance at all, and fees are lower. Do I still need health insurance? Yes. Direct Care covers primary and ongoing care, not hospitalization, surgery, or catastrophic events. Most members pair membership with a high-deductible plan. What if I need a specialist or hospital care? Your physician coordinates referrals and works with the specialist. Your insurance covers those services as it normally would. Direct Specialty Care practices are also an emerging option for insurance-free specialist access. Can I use HSA funds? Yes, as of January 1, 2026, up to $150/month individual or $300/month family. Can Medicare patients join? Generally yes, though Medicare will not reimburse an opted-out physician's services or the membership fee. Ask each practice how they are structured. How do I find a Direct Care practice near me? Search the DPC Frontier mapper or DPC Nation. For specialists, use the DSC Alliance directory. For Physicians: Resources for Starting Your Own Direct Care Practice If you are a physician considering the transition, the movement is far better supported than it was even five years ago. These are the organizations I recommend: DPC Frontier — The essential legal and regulatory resource. Their state-by-state guides cover defining legislation and insurance-law considerations, and their guidance on opting out of Medicare is required reading before you structure your practice. Direct Primary Care Alliance (DPCA) — The national 501(c)(6) focused solely on DPC physicians: education, mentorship, masterminds, group purchasing, and malpractice discounts. See membership benefits. Direct Specialty Care Alliance (DSC Alliance) — Founded in 2020 for specialists building insurance-free practices. Contracts, templates, and a structured starter course built for the specific challenges specialists face. DPC Coalition (DPCC) — The leading policy and advocacy organization, and the group behind the HSA legislative win. Free Market Medical Association (FMMA) — Broader price-transparency movement connecting physicians, patients, and self-funded employers. The San Antonio chapter is worth knowing for Texas physicians. DPC Nation — Patient-facing community and Facebook group. I have written a practical, unglamorous guide to the startup process — costs, entity formation, SEO, and the mistakes I made — here: So Doctor, Would You Like to Create Your Own Direct Primary Care Practice? The Bottom Line Direct Care is not a miracle or a movement requiring belief. It is a rearrangement of incentives. When a physician is paid to keep you well rather than to process encounters, prevention beats crisis management, patients come in early instead of waiting, and the adversarial triangle between patient, physician, and insurer collapses into an actual relationship. For integrative and functional medicine — where the work is slow, iterative, and deeply personal — that rearrangement is not a nicety. It is what makes the medicine possible at all. If you are managing a complex condition and want to discuss whether this approach fits your situation, you can learn more or reach out at directintegrativecare.com. About Dr. Kim Yoon Hang "John" Kim, MD, MPH, is board-certified in Preventive Medicine and is an Integrative & Functional Medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona's Andrew Weil Center for Integrative Medicine and holds certifications in preventive medicine, medical acupuncture, and integrative and holistic medicine. Dr. Kim specializes in low dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. He is the author of 3 books and over 20 published articles, and has helped establish integrative medicine programs at institutions nationwide. Yoon Hang Kim, MD, MPH Integrative & Functional Medicine Physician Based in San Antonio, Texas · Virtual practice serving TX, IA, IL, MO, FL, and GA www.yoonhangkim.com | www.directintegrativecare.com Related Reading Endorphins: Biochemistry, Bioregulation, and Clinical Levers Navigating Supplement and Medication Sequencing in ME/CFS–MCAS Overlap 15 Teaching Points from the LDN Support Group Pop-Up Live Pharmacogenomics and Naltrexone: Can Your Genes Predict How You Respond? Why Autoimmune Disease Affects Women More Often Than Men #DirectPrimaryCare #DirectCare #IntegrativeMedicine #FunctionalMedicine #DPC #MembershipMedicine #SanAntonio #RootCauseMedicine #HSA #PhysicianBurnout #PatientCentered References Kaiser Family Foundation. 2025 Employer Health Benefits Survey. October 2025. https://www.kff.org/health-costs/2025-employer-health-benefits-survey/ Mercer. Employers Prepare for the Highest Health Benefit Cost Increase in 15 Years. September 2025. https://www.mercer.com/en-us/insights/us-health-news/employers-prepare-for-the-highest-health-benefit-cost-increase-in-15-years/ Gunja MZ, et al. The Causes and Impacts of Burnout Among Primary Care Physicians in 10 Countries. Commonwealth Fund, November 2025. https://www.commonwealthfund.org/publications/surveys/2025/nov/causes-impacts-burnout-primary-care-physicians-10-countries Porter J, Boyd C, Skandari MR, Laiteerapong N. Revisiting the time needed to provide adult primary care. J Gen Intern Med. 2023;38(1):147–155. doi:10.1007/s11606-022-07707-x. PMID: 35776372. Sinsky CA, Shanafelt TD, Dyrbye LN, Sabety AH, Carlasare LE, West CP. Health care expenditures attributable to primary care physician overall and burnout-related turnover: a cross-sectional analysis. Mayo Clin Proc. 2022;97(4):693–702. doi:10.1016/j.mayocp.2021.09.013. PMID: 35339279. Society of Actuaries / Milliman. Direct Primary Care: Evaluating a New Model of Delivery and Financing. May 2020. https://www.milliman.com/en/insight/what-our-study-says-about-direct-primary-care American Academy of Family Physicians. Answers to six common questions about direct primary care (citing the AAFP 2024 DPC Data Brief; average panel size 402). https://www.aafp.org/pubs/fpm/blogs/inpractice/entry/dpc-faqs.html One Big Beautiful Bill Act (H.R. 1). Signed July 4, 2025; HSA/DPC provisions effective January 1, 2026. See IRS Revenue Procedure 2026-24 and IRS Notice 2026-05. DPC Frontier. Opting Out of Medicare. https://www.dpcfrontier.com/opting-out-of-medicare Direct Primary Care Coalition. https://www.dpcare.org/ Direct Primary Care Alliance. https://www.dpcalliance.org/ Direct Specialty Care Alliance. https://dscalliance.org/ Free Market Medical Association. https://fmma.org/

Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician www.directintegrativecare.com Disclaimer: This blog post is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Low dose naltrexone (LDN) is used off-label for essentially all of the conditions discussed below; it is not FDA-approved for any of them. Always consult with a qualified clinician before starting, adjusting, or discontinuing any medication. Individual responses to LDN vary considerably. One of the questions I hear most often in my practice is this: If I develop significant side effects from LDN, should I power through them? My answer depends on the level of side effect — but when they are significant, the answer is almost always no. When Rapid Titration Outpaces the Body's Capacity I recently worked with a patient who increased their dose very rapidly. The initial steps went smoothly — from 1 microgram (0.001 mg) to 5 micrograms (0.005 mg), no problems. But from there, the jumps to 10 and then 20 micrograms triggered significant side effects. This is not an unusual pattern. Individuals who are doing well at the lowest doses can be tempted — or advised — to move quickly toward higher targets. But the pace of titration matters at least as much as the destination dose. Side effects during a dose increase are not a signal to push harder; they are a signal that the increase was either too fast or too large for that person's system at that time. This pattern — tolerating very low doses well but encountering problems with larger jumps — is one of the most common and most avoidable sources of difficulty in LDN therapy.[1],[2] Why "Powering Through" Can Be the Wrong Move There is a common assumption, sometimes reinforced in online communities, that LDN side effects are just something to tolerate until the body adjusts. In some cases that is true — mild, transient vivid dreams or brief sleep disruption during the first one to two weeks often resolve without any change in dose.[3],[4] But when side effects are significant — meaning they interfere meaningfully with sleep, function, energy, mood, or quality of life — my standard recommendation is straightforward: stop the LDN. This is not a failure of the medication or of the patient. It is the safest way to reset the system, gather information, and plan a more careful approach. The Recovery Period: What It Involves and How Long It Takes Once LDN has been stopped, the next step is allowing the body enough time to recover before any restart is considered. In my clinical experience, this recovery window can range considerably depending on the individual: 3 to 7 days for mild-to-moderate reactions in otherwise non-sensitive individuals 7 to 14 days for more pronounced symptoms or moderately sensitive individuals 14 to 30 days for those with significant sensitivity syndromes, such as MCAS, ME/CFS, or conditions involving heightened nervous system reactivity The rationale for this recovery period involves several overlapping systems. The traditional proposed mechanism of LDN centers on a brief, partial blockade of opioid receptors followed by a compensatory upregulation of endogenous opioid production and receptor density — what some refer to as the "endorphin rebound."[5],[6] If a patient experiences significant adverse effects, the theory suggests that the opioid receptor system and related endorphin signaling need time to re-equilibrate before naltrexone is reintroduced. Editor's note on the endorphin rebound hypothesis: The concept that LDN's primary benefit derives from endorphin upregulation is widely cited, but the evidence is more nuanced than the popular narrative suggests. A 2021 study by Metz, Daimon, and Hentges in eNeuro examined whether LDN alters the activity of proopiomelanocortin (POMC) neurons in mice — the hypothalamic neurons responsible for producing β-endorphin — and found no evidence that LDN changed opioid receptor sensitivity on POMC neurons, Pomc mRNA production, or plasma β-endorphin levels.[7] The authors concluded that LDN's reported benefits appear to be independent of the POMC/β-endorphin pathway. This does not invalidate the clinical observation that a recovery period is needed after significant side effects. It does suggest that what is "recovering" may involve broader opioid receptor re-equilibration, glial and neuroinflammatory system resettling, or nervous system recalibration rather than a simple endorphin deficit. Animal data clearly show that naltrexone administration leads to robust mu-opioid receptor upregulation — increasing receptor density by as much as 93% — with gradual normalization over subsequent days.[8],[9] That receptor-level normalization, combined with the nervous system's broader adaptive response, likely contributes to the clinically observed need for a washout period before safe reinitiation. The honest summary: the recovery period is clinically real and well-supported by practice experience. The precise mechanism driving it is less settled than many accounts imply, and attributing it solely to "endorphin deficiency" oversimplifies the biology. Restarting Requires Expert Guidance After the recovery period, the patient should not simply resume at the same dose that caused difficulty. The appropriate restart strategy depends on the full clinical picture — what the side effect was, how severe it was, how sensitive the person's system has shown itself to be, and what underlying conditions are in play. In many cases, restarting at a substantially lower dose and titrating more slowly is sufficient. For highly sensitive individuals, the restart dose may need to be in the low microgram range — sometimes even lower — before any upward movement is attempted.[10] The specific dosing tiers (microgram, nanogram, and in rare cases picogram) and the pharmacologic rationale for them are discussed in greater detail in the companion post LDN Primer Follow-Up: What to Do When LDN Causes Side Effects. This is precisely the kind of decision that should be made in partnership with a clinician experienced in LDN titration across the full dosing spectrum — not self-directed based on another person's experience or a standardized protocol. The Value of Expert Guidance in LDN Therapy LDN is a powerful tool, but it is not a simple one. The difference between a productive LDN experience and a difficult one often comes down to the titration strategy — how quickly the dose is advanced, how side effects are interpreted, whether the clinician has the experience to recognize when a pause, a step back, or a reformulation is needed. If you have had to stop LDN because of side effects, that is not the end of the road. But the path forward should be individualized, informed by your specific response pattern, and guided by someone who understands the pharmacology and clinical nuance of this medication. Summary Step Action Side effects emerge Assess severity. Mild and transient symptoms (vivid dreams, brief sleep disruption) may resolve on their own within 1–2 weeks. Significant side effects Stop LDN. Do not attempt to push through symptoms that meaningfully impair function, sleep, or quality of life. Recovery period Allow the system to settle — typically 3 to 30 days depending on individual sensitivity and the severity of the reaction. Restart planning Work with an LDN-experienced clinician to determine the appropriate restart dose and titration schedule. The restart dose may be substantially lower than the dose that caused difficulty. #LDN #LowDoseNaltrexone #LDNSideEffects #IntegrativeMedicine #FunctionalMedicine #LDNTitration #ChronicPain #MCAS #LDNSupportGroup #EvidenceBasedMedicine References Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. doi:10.1007/s10067-014-2517-2. PMID: 24526250 Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohn's disease. Am J Gastroenterol. 2007;102(4):820–828. doi:10.1111/j.1572-0241.2007.01045.x. PMID: 17222320 (Sleep disturbance was the single most common side effect.) Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529–538. doi:10.1002/art.37734. PMID: 23359310 Toljan K, Vrooman B. Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization. Med Sci (Basel). 2018;6(4):82. doi:10.3390/medsci6040082. PMID: 30248938 Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. (Proposed mechanism includes temporary receptor blockade followed by compensatory endorphin upregulation and increased receptor density.) PMID: 24526250 Kim YH. Endorphins: Biochemistry, Bioregulation, and Clinical Levers. Integrative Functional Medicine and LDN Community (ifmsynergy.com). Published July 16, 2026. https://www.ifmsynergy.com/endorphins-biochemistry-bioregulation-and-clinical-levers/ Metz MJ, Daimon CM, Hentges ST. Reported benefits of low-dose naltrexone appear to be independent of the endogenous opioid system involving proopiomelanocortin neurons and β-endorphin. eNeuro. 2021;8(3):ENEURO.0087-21.2021. doi:10.1523/ENEURO.0087-21.2021. PMID: 34031099 Lesscher HMB, Bailey A, Burbach JP, van Ree JM, Kitchen I, Gerrits MAFM. Receptor-selective changes in μ-, δ- and κ-opioid receptors after chronic naltrexone treatment in mice. Eur J Neurosci. 2003;17(5):1006–1012. doi:10.1046/j.1460-9568.2003.02538.x. PMID: 12653976 Tempel A, Gardner EL, Zukin RS. Opioid antagonist modulation: naltrexone-induced receptor upregulation. Eur J Pharmacol. 1984;106(1):101–106. doi:10.1016/0014-2999(84)90683-9. PMID: 6152212 (Naltrexone treatment increased opioid receptor density by up to 93%, normalizing over subsequent days.) Kim YH. LDN Primer Follow-Up: What to Do When LDN Causes Side Effects. Integrative Functional Medicine and LDN Community (ifmsynergy.com). Published July 14, 2026. https://www.ifmsynergy.com/ldn-primer-follow-up-what-to-do-when-ldn-causes-side-effects/ Related Reading 15 Teaching Points from the LDN Support Group Pop-Up Live — An Evidence-Referenced Review Endorphins: Biochemistry, Bioregulation, and Clinical Levers Pharmacogenomics and Naltrexone: Can Your Genes Predict How You Respond? About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified physician with over 20 years of experience spanning preventive medicine, integrative and functional medicine, medical acupuncture, and integrative holistic medicine. A fellowship-trained graduate of the University of Arizona Center for Integrative Medicine under Dr. Andrew Weil, Dr. Kim specializes in low dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold-related illness. He is the author of three books and more than 20 published articles in integrative medicine. Professional: www.yoonhangkim.com Clinical: www.directintegrativecare.com

Beyond the Blue Pill: A Functional Medicine Approach to Erectile Dysfunction Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Medical Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Erectile dysfunction can be a sign of serious underlying health conditions, including cardiovascular disease. Always consult a qualified healthcare provider before starting any new treatment or supplement regimen. Nothing in this article should replace professional medical evaluation and management. Introduction: The Canary in the Coal Mine Erectile dysfunction (ED) affects an estimated 30 million men in the United States and over 150 million worldwide. Its prevalence rises sharply after age 40. In conventional medicine, the conversation often begins and ends with a prescription for a phosphodiesterase-5 (PDE-5) inhibitor—sildenafil, tadalafil, or one of their pharmacological cousins. These medications are effective for many men, but they treat the symptom without asking a more fundamental question: why is this happening in the first place? In functional and integrative medicine, we view ED not as an isolated mechanical failure but as a systemic signal—a canary in the coal mine that reflects deeper disruptions in vascular health, hormonal balance, metabolic function, gut integrity, and even psychological resilience. An erection, after all, is one of the most vascular-dependent events in human physiology. When the endothelial lining of blood vessels becomes compromised, the penile vasculature is often among the first casualties—frequently presenting years before a cardiovascular event like a heart attack or stroke. This article explores the root causes of ED through a functional medicine lens and outlines a comprehensive, evidence-informed approach to restoring sexual health by treating the whole person. The Nitric Oxide Connection: Where It All Begins At the molecular level, erectile function depends on nitric oxide (NO). Sexual stimulation triggers the release of NO from nerve endings and endothelial cells in the penile vasculature. NO activates soluble guanylyl cyclase, which increases cyclic guanosine monophosphate (cGMP), ultimately relaxing the smooth muscle of the corpus cavernosum and allowing blood engorgement. PDE-5 inhibitors work downstream in this cascade by preventing the breakdown of cGMP—but they cannot generate what isn't being produced in the first place. When the endothelium is damaged by chronic inflammation, oxidative stress, insulin resistance, or hyperlipidemia, NO bioavailability drops. This endothelial dysfunction is the shared pathophysiological highway connecting ED to cardiovascular disease, hypertension, diabetes, and metabolic syndrome. Research published in the Journal of Clinical Hypertension has confirmed that impaired NO signaling is the primary biochemical mechanism underlying organic ED. This insight is transformative for clinical practice. Rather than simply prescribing a PDE-5 inhibitor and moving on, a functional medicine approach asks: what is damaging the endothelium? What is suppressing NO production? And what can we do to restore it? Hormonal Terrain: More Than Just Testosterone Testosterone plays a well-established role in libido, arousal, and the maintenance of penile tissue health. Androgen deficiency is associated with penile smooth muscle atrophy, increased extracellular matrix deposition, and reduced expression of PDE-5 itself—which may explain why some hypogonadal men respond poorly to PDE-5 inhibitors alone. Testosterone replacement therapy has been shown to improve both erectile function scores and libido in hypogonadal men, and combination therapy with PDE-5 inhibitors may benefit those who fail monotherapy. However, testosterone is only one piece of a complex hormonal puzzle. A thorough functional medicine evaluation also considers: Estrogen balance: Elevated estradiol (often driven by aromatase activity in visceral adipose tissue) can suppress gonadotropin signaling and directly impair erectile function. Thyroid function: Both overt and subclinical hypothyroidism are associated with ED, partly through effects on vascular reactivity and partly through sexual desire. Cortisol and the HPA axis: Chronic stress and HPA axis dysregulation suppress gonadotropin-releasing hormone (GnRH) pulsatility, which in turn reduces luteinizing hormone (LH) and testosterone production. Cortisol also directly impairs NO-mediated vasodilation. Prolactin: Hyperprolactinemia, whether from medications (e.g., SSRIs, antipsychotics) or pituitary pathology, is a recognized but frequently overlooked cause of ED. DHEA-S and pregnenolone: These upstream adrenal precursors decline with age and chronic stress and may influence sexual function through downstream hormonal effects. Comprehensive hormonal testing—including total and free testosterone, SHBG, estradiol, DHEA-S, cortisol (ideally via a diurnal curve or DUTCH testing), thyroid panel, and prolactin—provides the detailed map needed to address hormonal contributors to ED. Metabolic and Vascular Health: The Foundation Metabolic syndrome—the clustering of central obesity, dyslipidemia, hyperglycemia, and hypertension—is one of the strongest predictive constellations for ED. Insulin resistance drives endothelial dysfunction through multiple mechanisms: increased oxidative stress, elevated advanced glycation end-products (AGEs), chronic low-grade inflammation, and impaired NO synthase activity. In men with diabetes, ED prevalence may exceed 50%, and it often appears a decade or more before overt cardiovascular events. A functional medicine approach to the metabolic root causes of ED includes: Dietary optimization: A Mediterranean-style dietary pattern, rich in polyphenols, omega-3 fatty acids, fiber, and nitrate-containing vegetables (beets, arugula, spinach), has been shown in clinical studies to improve erectile function in men with metabolic syndrome. Dietary nitrates are converted to NO via the enterosalivary nitrate-nitrite-NO pathway, providing an additional source of NO independent of endothelial synthase. Blood sugar regulation: Addressing insulin resistance through dietary carbohydrate modification, time-restricted eating, and targeted supplementation (berberine, chromium, alpha-lipoic acid) can improve endothelial function. Lipid management: Oxidized LDL is directly toxic to endothelial cells. Addressing lipid oxidation through anti-inflammatory nutrition and targeted antioxidants may protect the penile vasculature. Exercise: Regular aerobic and resistance exercise improves endothelial function, increases NO production, enhances insulin sensitivity, and supports testosterone production. Compound resistance training, in particular, has been associated with acute and chronic improvements in androgen levels. Weight management deserves special emphasis. Visceral adiposity increases aromatase activity (converting testosterone to estradiol), drives systemic inflammation, and contributes to insulin resistance—all of which converge on erectile dysfunction. The Gut-Vascular Axis: An Emerging Frontier One of the most compelling areas of emerging research in functional medicine connects gut health to erectile function through the gut-vascular axis. Studies comparing the gut microbiota of men with ED to healthy controls have revealed significant differences in microbial composition, including higher abundances of Bacteroides, Fusobacterium, and Escherichia-Shigella and lower abundances of Bifidobacterium in ED clients. Several mechanisms link gut dysbiosis to ED: TMAO production: Certain gut bacteria convert dietary choline, carnitine, and betaine into trimethylamine (TMA), which the liver oxidizes to trimethylamine N-oxide (TMAO). Elevated TMAO levels promote atherosclerotic plaque formation, vascular inflammation, and endothelial damage—all of which impair penile blood flow. Lipopolysaccharide (LPS) translocation: Gut barrier dysfunction (increased intestinal permeability) allows bacterial endotoxins like LPS to enter the systemic circulation, triggering NF-κB-mediated inflammatory cascades that damage vascular endothelium. Inflammatory cytokine signaling: Dysbiosis-driven elevations in IL-1β and IL-6 have been negatively correlated with beneficial bacterial populations and positively correlated with ED severity. Hormonal modulation: The gut-testes axis influences testosterone metabolism and the estrobolome (the collection of gut bacteria capable of metabolizing estrogens), potentially affecting androgen-estrogen balance. Addressing gut health in ED clients may involve comprehensive stool analysis, targeted antimicrobial or antifungal protocols for dysbiosis or overgrowth, prebiotic and probiotic support (particularly Bifidobacterium species), gut barrier restoration (glutamine, zinc carnosine, immunoglobulins), and dietary modification to reduce TMAO-generating substrates. Nitric Oxide Support: Nutraceutical Strategies Given the central role of NO in erectile physiology, targeted nutraceutical support aimed at restoring NO bioavailability represents a key pillar of the functional medicine approach. The evidence base, while still growing, supports several promising interventions: L-Citrulline: Unlike oral L-arginine, which undergoes extensive first-pass hepatic metabolism, L-citrulline bypasses the liver and is converted to L-arginine in the kidneys, raising systemic arginine levels more effectively and sustainably. A pilot trial of men with mild ED demonstrated that 1.5 g/day of L-citrulline for one month improved erection hardness scores in 50% of participants compared to 8.3% on placebo. Doses of 3–6 g/day are commonly used in clinical practice and are generally well tolerated. A randomized clinical trial is currently underway comparing L-citrulline 1,500 mg/day, tadalafil 5 mg/day, and their combination. L-Arginine: A multicenter, double-blind, randomized, placebo-controlled trial found that high-dose L-arginine (6 g/day) for three months significantly improved erectile function scores and cavernous artery peak systolic flow velocity in men with vasculogenic ED—particularly those with mild-to-moderate disease. A meta-analysis of ten RCTs has confirmed these benefits across varying dosages and durations. Pycnogenol (French Maritime Pine Bark Extract): When combined with L-arginine, pycnogenol has shown synergistic effects on erectile function, likely through its role as an endothelial NO synthase (eNOS) activator and antioxidant. Beetroot juice and dietary nitrates: Concentrated beet juice provides inorganic nitrate that oral bacteria convert to nitrite and subsequently to NO via the non-enzymatic pathway, supporting vasodilation independently of eNOS function. Trans-resveratrol: A randomized, double-blind, placebo-controlled crossover study found that oral L-citrulline combined with trans-resveratrol improved erectile function in men already using PDE-5 inhibitors, suggesting additive mechanisms. Homocysteine, Methylation, and the B-Vitamin Connection An often-overlooked contributor to erectile dysfunction is hyperhomocysteinemia—elevated levels of the amino acid homocysteine in the blood. Animal research has demonstrated that elevated homocysteine impairs erectile function by directly reducing endothelial nitric oxide synthase (eNOS) activity and increasing oxidative stress in the cavernous tissue. Importantly, supplementation with B vitamins (particularly B6, B12, and folate) has been shown to mitigate these effects. In functional medicine practice, assessing homocysteine levels, methylation status (including MTHFR polymorphisms), and B-vitamin adequacy is a standard part of the workup for ED. Targeted methylation support—using methylfolate, methylcobalamin, and pyridoxal-5-phosphate—may address this upstream vascular risk factor. Psychological Health, Sleep, and Stress No functional medicine discussion of ED is complete without addressing the psychological and lifestyle dimensions. Performance anxiety, relationship conflict, depression, and unresolved trauma can all drive or perpetuate erectile difficulties, often creating a vicious cycle in which a single episode of difficulty generates anticipatory anxiety that ensures recurrence. Sleep quality and duration are frequently underappreciated. Testosterone production follows a circadian rhythm and is closely tied to REM sleep. Sleep apnea, in particular, is strongly associated with both ED and low testosterone, and CPAP therapy has been shown to improve sexual function in some men. A sleep evaluation—ideally including home sleep testing when obstructive sleep apnea is suspected—should be part of any comprehensive ED assessment. Chronic stress, through sustained HPA axis activation, depletes DHEA and testosterone while simultaneously elevating cortisol, which impairs NO-mediated vasodilation and reduces libido. Stress-management interventions—including mindfulness-based stress reduction, cognitive behavioral therapy, breathwork, and adaptogenic herbs (ashwagandha, rhodiola)—can play a meaningful therapeutic role. Medication-Induced ED: A Functional Medicine Red Flag A thorough functional medicine evaluation always includes a careful medication review. Many commonly prescribed drugs contribute to or cause ED, including: Antihypertensives: Thiazide diuretics and older beta-blockers (e.g., atenolol, metoprolol) are well-known offenders. Newer beta-blockers (nebivolol) and ARBs tend to be more sexually neutral. SSRIs and SNRIs: Serotonergic antidepressants cause sexual dysfunction—including ED, delayed ejaculation, and anorgasmia—in up to 70% of users. Statins: While the data is mixed, some men report sexual side effects on HMG-CoA reductase inhibitors, possibly through effects on cholesterol-dependent hormone synthesis. 5-alpha reductase inhibitors: Finasteride and dutasteride (used for BPH and hair loss) can cause persistent sexual dysfunction in a subset of men. Opioids: Chronic opioid use suppresses the hypothalamic-pituitary-gonadal axis, leading to hypogonadism and ED. In functional and integrative medicine, we explore whether root-cause treatment of the conditions these medications were prescribed for might allow dose reduction or discontinuation—always in collaboration with the prescribing clinician. Putting It All Together: The Functional Medicine Workup A comprehensive functional medicine evaluation for ED integrates the following components: Detailed history: Onset pattern (sudden vs. gradual), nocturnal/morning erections, situational versus global dysfunction, psychosocial stressors, relationship dynamics, medication and supplement review, sleep quality, exercise habits, and dietary patterns. Advanced laboratory assessment: Comprehensive metabolic panel, fasting insulin, HbA1c, lipid panel with particle size, high-sensitivity CRP, homocysteine, complete thyroid panel (TSH, free T3, free T4, thyroid antibodies), total and free testosterone, SHBG, estradiol, DHEA-S, prolactin, cortisol (AM or diurnal), vitamin D, B12, folate, RBC magnesium, and ferritin. Specialized testing as indicated: DUTCH hormone testing (for detailed androgen and cortisol metabolite analysis), comprehensive stool analysis (for gut microbiome and barrier assessment), organic acids testing, and pharmacogenomic testing (particularly relevant when considering medication adjustments). Cardiovascular assessment: Given that ED may precede cardiovascular events by 3–5 years, appropriate cardiovascular screening (coronary artery calcium score, carotid intima-media thickness, or advanced lipid testing) should be considered, especially in men over 40 presenting with new-onset ED. Conclusion: Treating the Man, Not Just the Erection Erectile dysfunction is far more than a bedroom inconvenience. It is a systemic health signal that, when properly interpreted, can reveal reversible root causes spanning vascular damage, hormonal imbalance, metabolic dysfunction, gut dysbiosis, nutritional deficiency, medication side effects, and psychological distress. PDE-5 inhibitors have their place—they are effective, well-studied, and sometimes necessary—but they are a symptom-management tool, not a root-cause solution. Functional and integrative medicine offers men a different path: a thorough investigation of the why behind the dysfunction, followed by a personalized, multimodal treatment plan that addresses the underlying biology. In doing so, we often improve not just erectile function but overall cardiovascular risk, metabolic health, energy, mood, and quality of life. If you are experiencing erectile dysfunction and want to explore a root-cause approach, consider working with a functional medicine clinician who can provide the comprehensive evaluation and individualized treatment plan that this condition deserves. To learn more about a functional and integrative medicine approach to men's health, visit www.directintegrativecare.com. ________________________________________ About Dr. Kim Dr. Yoon Hang “John” Kim is board-certified in Preventive Medicine and certified in Integrative and Holistic Medicine, Medical Acupuncture (UCLA), and Functional Medicine (IFM Scholar). With over 20 years of clinical experience, he completed his fellowship training under Dr. Andrew Weil at the University of Arizona Center for Integrative Medicine. He specializes in low dose naltrexone (LDN) therapy, autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold-related illness. He is the author of three books and more than 20 peer-reviewed publications. Professional: www.yoonhangkim.com Clinical: www.directintegrativecare.com References Burnett AL. The role of nitric oxide in erectile dysfunction: implications for medical therapy. J Clin Hypertens (Greenwich). 2006;8(12 Suppl 4):53-62. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151(1):54-61. Cormio L, De Siati M, Lorusso F, et al. Oral L-citrulline supplementation improves erection hardness in men with mild erectile dysfunction. Urology. 2011;77(1):119-122. Menafra D, de Angelis C, Garifalos F, et al. Long-term high-dose L-arginine supplementation in patients with vasculogenic erectile dysfunction: a multicentre, double-blind, randomized, placebo-controlled clinical trial. J Endocrinol Invest. 2022;45(5):941-961. Zhao M, Yuan L, Liang S, et al. Gut microbiota composition may be an indicator of erectile dysfunction. MicrobiologyOpen. 2024;13(1):e1397. Liu S, Li C, Qin Y, et al. Correlation between gut microbiota diversity and psychogenic erectile dysfunction. Transl Androl Urol. 2021;10(12):4412-4421. Jiang W, Xiong L, Li W, et al. Hyperhomocysteinaemia in rats is associated with erectile dysfunction by impairing endothelial nitric oxide synthase activity. Sci Rep. 2016;6:26647. Rizk PJ, Kohn TP, Pastuszak AW, Khera M. Testosterone therapy improves erectile function and libido in hypogonadal men. Curr Opin Urol. 2017;27(6):511-515. Esposito K, Ciotola M, Giugliano F, et al. Mediterranean diet improves erectile function in subjects with the metabolic syndrome. Int J Impot Res. 2006;18(4):405-410. 10. Wang X, Xie Z. Trimethylamine N-oxide and erectile dysfunction: a review of the gut-vascular axis. Front Endocrinol (Lausanne). 2022;13:1003891. 11. Schwedhelm E, Maas R, Freese R, et al. Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism. Br J Clin Pharmacol. 2008;65(1):51-59. 12. Colao A, Pivonello R, et al. Integrative natural approaches for age-related testosterone decline: a synergistic framework combining exercise, nutrition, and bioactive compounds. Nutrients. 2025;17(4):XXX. 13. Osman A, et al. Comparison of the gut microbiome composition between men with erectile dysfunction and a matched cohort: a pilot study. Andrology. 2024;12(1):45-55. 14. Fortney L. Erectile dysfunction. In: Rakel D, ed. Integrative Medicine. 4th ed. Elsevier; 2018:623-629.e2.

www.directintegrativecare.com The Layered Approach to Mast Cell Activation Syndrome: Integrating Dr. Afrin's Framework with Functional Medicine Therapeutics LDN, Ketotifen, Methylene Blue, Quercetin, and Luteolin in a Stepwise Clinical Model Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Medical Disclaimer This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Mast Cell Activation Syndrome (MCAS) management must be individualized under the guidance of a qualified healthcare provider. Do not start, stop, or modify any treatment based on this information alone. Always consult your physician before making changes to your care plan. Introduction: Why a Layered Approach Is Necessary Mast Cell Activation Syndrome (MCAS) is a condition in which mast cells—normally protective immune sentinels stationed throughout connective tissue, mucosal surfaces, and perivascular spaces—become chronically dysregulated, releasing a disproportionate cascade of mediators including histamine, prostaglandins, leukotrienes, tryptase, and cytokines. The clinical result is a multi-system inflammatory syndrome that can mimic dozens of other conditions, presenting with symptoms spanning the gastrointestinal, dermatologic, cardiovascular, neuropsychiatric, and musculoskeletal systems simultaneously. What makes MCAS particularly challenging is not simply the breadth of symptoms but the heterogeneity of individual mediator profiles. No two clients present identically. Dr. Lawrence Afrin, a hematologist-oncologist widely regarded as the foremost clinical authority on mast cell disease, has remarked in interviews that he did not encounter a case bearing reasonable similarity to any previous one until he had seen roughly seventy MCAS clients—an anecdotal observation rather than a published statistic, but one that captures the extraordinary biological variability at the core of this condition. This heterogeneity demands a layered, stepwise treatment strategy—one that builds sequentially, adds one intervention at a time, and allows for careful clinical observation at each stage. Dr. Afrin's guiding principles of patience, persistence, and a methodical approach remain the gold standard for MCAS management. The functional and integrative medicine framework extends this further by incorporating immunomodulatory agents, natural mast cell stabilizers, and mitochondrial support that address not only mediator blockade but root-cause drivers of mast cell dysfunction. This article presents a layered clinical model that integrates Dr. Afrin's foundational pharmacologic approach with the functional medicine toolkit I employ at www.directintegrativecare.com—specifically incorporating low-dose naltrexone (LDN), ketotifen, methylene blue (MB), quercetin, and luteolin. Cross-references to prior clinical reviews published on this topic are available at ifmsynergy.com/tag/mcas. Layer 1: The Afrin Foundation — H1 and H2 Antihistamines Every published treatment algorithm for MCAS begins with dual histamine receptor blockade. This is not optional—it is the pharmacologic floor upon which all subsequent layers are built. Histamine acts on four receptor subtypes (H1 through H4), but currently available therapeutics target only H1 and H2. By blocking both receptor classes simultaneously, clinicians achieve broader coverage of histamine-mediated symptoms including flushing, pruritus, urticaria, tachycardia, gastrointestinal distress, and headache. A point of mechanistic precision is warranted here, because a claim circulating widely in the integrative MCAS literature is stated backwards. It is often asserted that famotidine stabilizes mast cells because H2 receptors sit on the mast cell surface. Human mast cells do express H2 receptors—but H2 signaling on the mast cell raises intracellular cAMP and inhibits mediator release, functioning as a negative-feedback brake. Blocking that receptor does not stabilize the mast cell. The sound rationale for H2 blockade in MCAS is different and still compelling: H2 receptors are widely distributed on target tissues throughout the gastrointestinal tract, cardiovascular system, and elsewhere, so H2 antagonism blocks a large share of histamine's downstream effects that H1 blockade leaves untouched. A proton pump inhibitor does not substitute, because it suppresses acid production rather than blocking histamine at its receptor. Second-generation H1 antihistamines such as cetirizine or fexofenadine are preferred over first-generation agents (diphenhydramine, hydroxyzine) due to their superior side effect profiles and longer half-lives. MCAS clients frequently require doses at two to four times FDA-approved levels under medical supervision. These medications work prophylactically—once histamine-mediated symptoms appear, receptor binding has already occurred, and the therapeutic window has been missed. This foundational layer alone provides meaningful symptom reduction in most MCAS clients. Dr. Afrin has observed that a fortunate subset achieves satisfactory control with H1/H2 blockade alone. For the majority, however, this layer establishes a baseline from which additional agents are methodically introduced. Layer 2: Mast Cell Stabilization — Ketotifen and Cromolyn Sodium When antihistamines alone do not provide adequate control, the next logical escalation is the addition of agents that prevent mast cell degranulation itself—shifting the strategy from blocking released mediators to preventing their release in the first place. Ketotifen: Dual-Action Systemic Stabilizer Ketotifen occupies a unique pharmacologic niche as both a mast cell stabilizer and an H1 antihistamine. This dual mechanism makes it particularly valuable in MCAS management. Its stabilizing action involves inhibition of calcium influx across mast cell membranes, which reduces the release of histamine, tryptase, prostaglandins, and other mediators. Simultaneously, its H1 receptor antagonism provides an additional layer of histamine blockade beyond what cetirizine or fexofenadine provide alone. In functional medicine practice, ketotifen is frequently used as a bridge therapy—providing symptom control while deeper root causes such as gut dysbiosis, mold exposure, chronic infections, or heavy metal burden are being identified and addressed. It is available in the United States primarily through compounding pharmacies, as the oral formulation is not commercially marketed domestically. Common starting doses range from 0.5 to 1 mg at bedtime, with titration guided by clinical response and side effects (primarily initial sedation). Maximum therapeutic effect typically requires six to twelve weeks of consistent use—a timeline that reinforces Dr. Afrin's emphasis on patience in MCAS management. Cromolyn Sodium: The GI-Focused Stabilizer Cromolyn sodium remains the gold standard for GI-predominant MCAS presentations. Its negligible systemic absorption (less than one percent reaches the circulation) means it acts almost exclusively at the mucosal surface of the gastrointestinal tract—precisely where a high concentration of mast cells resides. This local action makes it particularly effective for abdominal pain, nausea, bloating, diarrhea, and food-related mast cell activation without introducing systemic side effects. Cromolyn requires slow introduction in sensitive MCAS clients, often beginning at one-quarter of an ampule and titrating upward over weeks. Full therapeutic benefit may take four to eight weeks to manifest. It is available as an oral solution (Gastrocrom) or can be compounded into capsules for clients sensitive to the liquid formulation's excipients. Layer 3: Immunomodulation — Low-Dose Naltrexone (LDN) The third layer introduces a mechanistic shift from mediator blockade and mast cell stabilization to upstream immunomodulation. Low-dose naltrexone represents one of the most compelling additions to the MCAS treatment algorithm, operating through pathways distinct from any antihistamine or stabilizer. At doses of 0.5 to 4.5 mg daily (typically administered at bedtime), LDN functions as a short-acting mu-opioid antagonist that transiently blocks opioid receptors. This paradoxical blockade triggers a compensatory upregulation of endogenous endorphins and enkephalins—peptides that do far more than modulate pain and mood. They bind to regulatory T cells, influencing T-lymphocyte and B-lymphocyte production and thereby recalibrating the adaptive immune response. The mechanisms by which LDN may benefit MCAS are multi-layered, though it should be said plainly that they are inferred from adjacent literature rather than demonstrated in MCAS clients directly. LDN antagonizes Toll-like receptor 4 (TLR4), a pattern recognition receptor whose activation drives NF-κB-mediated inflammatory cascades; TLR4 is expressed on mast cells and microglia alike, and its inhibition reduces production of pro-inflammatory cytokines including IL-6 and TNF-α while promoting anti-inflammatory mediators such as IL-10. LDN also modulates microglial activation, a mechanism with particular relevance for clients presenting with neuroinflammation, brain fog, and neuropsychiatric symptoms. A further proposed pathway is that T-cell microparticles activate mast cells and that LDN's reduction of excessive T-cell dysfunction disrupts this loop—this remains a hypothesis rather than an established mechanism, and Weinstock, who proposed it, has been explicit that the existence of opioid receptors on mast cells themselves is not clear. The clinical evidence base consists of case reports, small case series, and uncontrolled clinical audits rather than randomized controlled trials, and the figures deserve to be stated precisely rather than rounded upward. In the frequently cited 2018 BMJ Case Report by Weinstock and colleagues, a client with severe POTS and MCAS received ultra-low-dose naltrexone at 1 mg nightly; after six weeks this produced a 7% decrease in POTS severity scores and a 17% decrease in MCAS severity scores, with improvement in body pain, mood, memory, sleep, flushing, odor and food sensitivities, and paresthesia. Larger gains followed the subsequent addition of IVIg and rifaximin, so the composite response reported in that case cannot be attributed to naltrexone alone. A figure widely quoted as "LDN Research Trust data" is more accurately described as Dr. Leonard Weinstock's own unpublished clinical audit, presented in a video interview hosted by the Trust. In that series of 116 MCAS clients, 60% reported some improvement, 20% reported no effect, and 20% discontinued because of side effects—a discontinuation rate that is unsurprising given how frequently MCAS clients react to medications and excipients. Within the 70 clients who improved, the symptom-level numbers are small and should not be overstated: abdominal pain improved in 15, joint pain and fatigue in 11 each, muscle pain in 9, diarrhea in 6, constipation and restless legs in 5 each, and reduction in mast cell flares specifically in only 4. A 2025 clinical audit from University Hospitals of Leicester provides a second uncontrolled data point: 40 MCAS clients treated with LDN alone showed improvement in joint pain, fatigue, and gastrointestinal and skin symptoms, while 20 did not tolerate the medication. All clients in that cohort were already receiving antihistamines and mast cell stabilizers before LDN was added, which is consistent with the layered model described here—LDN was an addition to a foundation, not a replacement for it. In my clinical practice, LDN is positioned at Layer 3 because it addresses a fundamentally different axis of MCAS pathophysiology—immune dysregulation—rather than simply blocking mediators or stabilizing membranes. For a detailed mechanistic review, see my prior article: Why Low-Dose Naltrexone Calms Mast Cells. Layer 4: Natural Mast Cell Stabilizers — Quercetin and Luteolin The fourth layer incorporates natural flavonoids that provide mast cell stabilization through mechanisms complementary to pharmaceutical agents. Quercetin and luteolin are the two most extensively studied natural mast cell stabilizers and are widely used in integrative MCAS management. Quercetin Quercetin is a bioflavonoid found in onions, apples, berries, and green tea that inhibits the release of histamine, tryptase, and pro-inflammatory cytokines from mast cells. Its mechanism involves modulation of intracellular calcium signaling, inhibition of NF-κB activation, and suppression of protein kinase C pathways involved in mast cell degranulation. It also inhibits the release of prostaglandins and leukotrienes, addressing mediator pathways beyond histamine alone. The primary limitation of quercetin is poor oral bioavailability—absorption of standard formulations is low enough that the plasma concentrations achieved in humans fall well below those used in the cell culture experiments that demonstrate mast cell inhibition. This gap between in vitro potency and in vivo exposure is the central caveat for all flavonoid therapy. Liposomal or phytosome-complexed preparations improve absorption and are preferred in clinical practice. Typical dosing ranges from 500 to 1,000 mg daily, often combined with vitamin C, which is reported to support diamine oxidase activity and histamine metabolism—though the human evidence for that specific interaction is modest. While most mechanistic studies remain preclinical, the favorable safety profile and the broad anti-inflammatory, antioxidant, and mast cell stabilizing properties of quercetin make it a rational addition to the MCAS treatment stack, particularly for clients who are sensitive to pharmaceutical agents or prefer to minimize medication burden. Luteolin Luteolin, found in celery, chamomile, green peppers, and parsley, shares quercetin's mast cell stabilizing properties but offers distinct advantages, particularly for neuroinflammatory presentations. Research demonstrates that luteolin inhibits mast cell activation by suppressing intracellular calcium influx and blocking protein kinase C activation—the same signaling pathways through which the related flavonols act. It is worth noting that the published head-to-head comparison against cromolyn was conducted with quercetin, not luteolin; claims that luteolin specifically outperforms cromolyn are frequently repeated in the integrative literature but are extrapolated rather than directly demonstrated. What distinguishes luteolin from quercetin is its ability to cross the blood-brain barrier. This makes it uniquely valuable for MCAS clients suffering from neuroinflammation, brain fog, and cognitive dysfunction, as it can directly modulate mast cells residing in the central nervous system and reduce microglial activation. For a comprehensive review, see: Luteolin for MCAS: A Natural Mast Cell Stabilizer Worth Understanding. In practice, quercetin and luteolin are often used in combination, as their complementary mechanisms—quercetin's broader systemic anti-inflammatory profile and luteolin's CNS penetration—provide more comprehensive coverage than either agent alone. Liposomal formulations of both are preferred for bioavailability. Typical luteolin dosing ranges from 100 to 300 mg daily. Layer 5: Mitochondrial and Neuroimmune Support — Methylene Blue The fifth layer introduces methylene blue (MB), a re-emerging therapeutic agent that occupies a unique position in the MCAS toolkit by addressing the mitochondrial dimension of mast cell dysfunction—a mechanism that no conventional antihistamine, mast cell stabilizer, or immunomodulator directly targets. Mast cells are metabolically active cells that depend heavily on mitochondrial function for both mediator synthesis and degranulation signaling. When mitochondrial function is compromised—whether from oxidative stress, chronic infection, environmental toxin exposure, or genetic polymorphisms—mast cells become more reactive and less responsive to stabilizing interventions. This is the pathophysiologic rationale for incorporating mitochondrial support into the MCAS treatment algorithm. At the low oral doses used in integrative practice—generally in the range of 5 to 20 mg daily, or roughly 0.1 to 0.3 mg/kg, well below the milligram-per-kilogram dosing used acutely for methemoglobinemia—methylene blue acts as an alternative electron carrier in the mitochondrial electron transport chain. It shuttles electrons between Complex I and Complex III, bypassing dysfunctional segments and restoring ATP production while simultaneously reducing the generation of reactive oxygen species (ROS). This dual action—enhanced energy output with reduced oxidative stress—directly supports cellular resilience, including mast cell membrane stability. Beyond its mitochondrial effects, methylene blue inhibits the nitric oxide–cyclic GMP (NO-cGMP) pathway, which has direct relevance to MCAS. Excessive nitric oxide production is implicated in mast cell-mediated vasodilation, flushing, and the vasomotor instability seen in POTS-MCAS overlap presentations. By downregulating cGMP, methylene blue may reduce both inflammatory signaling and vascular symptoms. Additionally, MB has demonstrated neuroprotective properties—crossing the blood-brain barrier and reducing microglial-mediated neuroinflammation, making it complementary to luteolin in addressing neuropsychiatric MCAS manifestations. Methylene blue does carry important precautions. It is contraindicated with serotonergic medications (SSRIs, SNRIs, MAOIs) due to the risk of serotonin syndrome. G6PD deficiency must be ruled out prior to initiation. Clients should be informed that MB will turn urine blue-green—a harmless but sometimes alarming effect. For a full review, see: Low Dose Methylene Blue in Functional Medicine. Clinical Algorithm: Matching Layers to Client Phenotype The layered model is not rigidly sequential for every client. The clinical art lies in identifying the predominant phenotype and selecting the layers most relevant to each individual's presentation. The following table maps common MCAS phenotypes to recommended layer priorities: Client Phenotype Layer 1 Foundation Layer 2–3 Escalation Rationale GI-Predominant H1/H2 blockers + Cromolyn Ketotifen, LDN, DAO enzymes Cromolyn acts locally with <1% absorption; ketotifen adds systemic stabilization Skin / Respiratory H1/H2 blockers + Ketotifen Quercetin, Luteolin, Cromolyn nasal Dual H1 blockade + mast cell stabilization; flavonoids reduce mediator release Neuroinflammatory / Brain Fog H1/H2 blockers + LDN Luteolin, Methylene Blue LDN modulates TLR4/microglia; luteolin crosses BBB; MB supports mitochondria Vasomotor / POTS Overlap H1/H2 blockers + LDN Ketotifen, Methylene Blue LDN + MB address NO pathway and flushing; ketotifen for systemic stabilization Multi-System / Refractory H1/H2 + Ketotifen + LDN MB, Quercetin/Luteolin, Cromolyn Layered combination across all mediator pathways; consider biologics if refractory Table adapted from clinical algorithms published at ifmsynergy.com/tag/mcas. All interventions require individualization under clinical supervision. Guiding Principles: The Afrin Framework Applied Dr. Afrin's three principles—patience, persistence, and a methodical approach—are not merely philosophical aspirations; they are clinical necessities. MCAS is not a condition that yields to aggressive polypharmacy or rapid-fire therapeutic changes. Each layer should be introduced as a single variable, maintained for an adequate trial period (typically four to twelve weeks depending on the agent), and assessed for both benefit and adverse effects before the next layer is added. This methodical escalation serves multiple purposes. It allows clinicians to identify which specific agents are producing benefit (or causing reactions), avoids the confounding effects of simultaneous multi-agent introduction, and respects the exquisite sensitivity that many MCAS clients have to new substances—including the very medications intended to help them. Even beneficial agents like cromolyn sodium and ketotifen can initially worsen symptoms in hypersensitive individuals if introduced too rapidly. The layered model also acknowledges that MCAS management is not about achieving perfection. The realistic clinical goal, as Dr. Afrin has articulated, is to help clients feel significantly better than their pre-treatment baseline the majority of the time. This is an important expectation to set, as both clinicians and clients benefit from understanding that complete symptom resolution is rarely achievable—but substantial, meaningful improvement is well within reach for most clients who pursue methodical, layered treatment. Conclusion MCAS requires a treatment approach as complex and individualized as the condition itself. The layered model presented here—antihistamine foundation, mast cell stabilization, immunomodulation with LDN, natural flavonoid support with quercetin and luteolin, and mitochondrial optimization with methylene blue—represents a synthesis of Dr. Afrin's evidence-based pharmacologic framework with the root-cause-oriented perspective of functional medicine. No single agent addresses all dimensions of mast cell dysregulation. Histamine blockade alone does not prevent degranulation. Stabilizers alone do not modulate the upstream immune signaling that drives mast cell hyperreactivity. Immunomodulators alone do not correct the mitochondrial dysfunction that makes mast cells more vulnerable to activation in the first place. It is the layered integration of these distinct mechanisms—each building upon and complementing the others—that offers clients the most comprehensive path toward stabilization and improved quality of life. The evidence base for several of these agents continues to evolve. Clinicians and clients alike must hold the tension between biological plausibility and the current limitations of rigorous clinical trial data. What is clear is that MCAS is treatable, that most clients can achieve meaningful improvement, and that the methodical, layered approach remains the most reliable path to that outcome. References Weinstock LB, Brook JB, Myers TL, Goodman B. Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. BMJ Case Reports. 2018;2018:bcr-2017-221405. doi:10.1136/bcr-2017-221405 Molderings GJ, Haenisch B, Brettner S, Homann J, Menzen M, Dumoulin FL, Panse J, Butterfield J, Afrin LB. Pharmacological treatment options for mast cell activation disease. Naunyn-Schmiedeberg's Archives of Pharmacology. 2016;389(7):671–694. doi:10.1007/s00210-016-1247-1 Afrin LB, Butterfield JH, Raithel M, Molderings GJ. Often seen, rarely recognized: mast cell activation disease—a guide to diagnosis and therapeutic options. Annals of Medicine. 2016;48(3):190–201. doi:10.3109/07853890.2016.1161231 Toljan K, Vrooman B. Low-dose naltrexone (LDN)—Review of therapeutic utilization. Medical Sciences. 2018;6(4):82. Theoharides TC, Tsilioni I, Bawazeer M. Mast cells, neuroinflammation and pain in fibromyalgia syndrome. Frontiers in Cellular Neuroscience. 2019;13:353. Kempuraj D, Madhappan B, Christodoulou S, Boucher W, Cao J, Papadopoulou N, Cetrulo CL, Theoharides TC. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. British Journal of Pharmacology. 2005;145(7):934–944. doi:10.1038/sj.bjp.0706246 Theoharides TC. Luteolin as a therapeutic option for multiple sclerosis. Journal of Neuroinflammation. 2009;6:29. doi:10.1186/1742-2094-6-29 Xiong ZM, Choi JY, Wang K, et al. Methylene blue alleviates nuclear and mitochondrial abnormalities in progeria. Aging Cell. 2016;15(2):279–290. doi:10.1111/acel.12434 [Cited for methylene blue's mitochondrial-antioxidant mechanism; this study examined progeria fibroblasts, not mast cells.] Myers B, et al. Use of low dose naltrexone and hydroxycarbamide for mast cell disorders (ISM, MCAS, HaT). Journal of Cancer Prevention & Current Research. 2025;16(5):134–135. [Mini review / clinical audit, University Hospitals of Leicester, UK.] Weinstock LB, Brook JB, Molderings GJ. Efficacy and toxicity of hydroxyurea in mast cell activation syndrome patients refractory to standard medical therapy: retrospective case series. Naunyn-Schmiedeberg's Archives of Pharmacology. 2022;395(11):1441–1447. doi:10.1007/s00210-022-02282-8 Lippert U, Artuc M, Grützkau A, Babina M, Guhl S, Haase I, et al. Human skin mast cells express H2 and H4, but not H3 receptors. Journal of Investigative Dermatology. 2004;123(1):116–123. doi:10.1111/j.0022-202X.2004.22721.x Cardet JC, Castells MC, Hamilton MJ. Immunology and clinical manifestations of non-clonal mast cell activation syndrome. Current Allergy and Asthma Reports. 2013;13(1):10–18. doi:10.1007/s11882-012-0326-8 Weng Z, Zhang B, Asadi S, Sismanopoulos N, Butcher A, Fu X, Katsarou-Katsari A, Antoniou C, Theoharides TC. Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humans. PLoS One. 2012;7(3):e33805. doi:10.1371/journal.pone.0033805 Note on evidence quality: References above were individually verified against primary sources. Readers should note that the flavonoid data (quercetin, luteolin) derive predominantly from in vitro and preclinical models; the methylene blue mitochondrial literature is largely non-mast-cell; and the LDN evidence in MCAS consists of case reports, case series, and registry data rather than randomized controlled trials. No agent discussed in this article is FDA-approved for MCAS. About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified physician with over 20 years of clinical experience. A graduate of the University of Arizona Integrative Medicine Fellowship (Osher Fellow under Dr. Andrew Weil), he holds board certifications in Preventive Medicine and Integrative & Holistic Medicine, along with UCLA medical acupuncture certification and IFM Scholar status. He specializes in low-dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome, and mold toxicity. He is the author of 3 books and over 20 peer-reviewed articles. Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com Keywords: MCAS, Mast Cell Activation Syndrome, layered treatment, LDN, low-dose naltrexone, ketotifen, methylene blue, quercetin, luteolin, mast cell stabilizer, functional medicine, integrative medicine, Dr. Afrin, histamine, cromolyn sodium, neuroinflammation, POTS

Why Work With Dr. Yoon Hang Kim for LDN Therapy: The Membership Model Advantage for Complex Conditions Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician If you're living with a complex, multi-system condition — Mast Cell Activation Syndrome, POTS, autoimmune disease, fibromyalgia, chronic Lyme, CRPS, or a cancer diagnosis where you're looking for evidence-informed adjunctive support — you've probably already learned a hard truth: conventional care wasn't built for you. Fifteen-minute visits, rotating providers, and rigid dosing protocols don't leave much room for the kind of careful, iterative work that conditions like these actually require. Low Dose Naltrexone (LDN) is a perfect example of why this matters. It's not a drug you start once and forget. LDN modulates immune signaling, calms neuroinflammation, and supports endorphin regulation — but how it does that for you depends on your specific condition, your other medications, your genetics, and how your body responds over time. Getting LDN right isn't a single decision. It's a relationship. And the physician guiding that relationship matters enormously. Why Dr. Kim: A Career Built Around LDN and Complex Conditions Yoon Hang "John" Kim, MD, MPH, isn't a physician who added LDN to a general practice as an afterthought. His clinical career, research, and leadership roles have been centered on the intersection of integrative medicine and complex chronic illness for over two decades. Dr. Kim completed a residential fellowship as an Osher Fellow under Dr. Andrew Weil at the University of Arizona — the gold standard in integrative medicine training. He holds a Master of Public Health, completed the UCLA Medical Acupuncture Training Program, and is board-certified in both Preventive Medicine and Integrative & Holistic Medicine. He holds IFM Scholar status and has authored 3 books — including the LDN Primer and a clinical LDN textbook — along with more than 20 peer-reviewed articles. His leadership positions reflect the same focus. Dr. Kim served as Medical Director of the Integrative Oncology Program at Miami Cancer Institute and as Director of the University of Kansas Medical Center Integrative Medicine Program, in addition to leadership roles at WellMed/Optum. These weren't administrative titles; they were program-building roles that required designing integrative protocols for medically complex populations — exactly the kind of clinical thinking LDN demands. A Depth of LDN Expertise That Few Physicians Can Match What sets Dr. Kim apart from the growing number of practitioners who prescribe LDN is the breadth and depth of his work with the therapy across multiple clinical domains: Chronic pain and autoimmune conditions: Dr. Kim uses LDN extensively for clients managing Complex Regional Pain Syndrome (CRPS), fibromyalgia, multiple sclerosis, Crohn's disease, MCAS, POTS, ME/CFS, chronic Lyme, endometriosis, PANS/PANDAS, and a wide range of autoimmune disorders. These aren't conditions where a standard starting dose and a follow-up in three months will suffice — they require a physician who understands how LDN interacts with each of these disease processes individually. Ultra-Low Dose Naltrexone (ULDN): In a 2019 peer-reviewed paper, Dr. Kim explored the clinical use of ultra-low dose naltrexone — microgram-level dosing — for chronic pain. His research highlights how ULDN can work synergistically with pain relief pathways, including augmenting opioid medications while reducing tolerance and enhancing the effects of acupuncture. This level of pharmacologic nuance matters when your condition doesn't respond to conventional LDN dosing alone. Pharmacogenomics and individualized dosing: Dr. Kim incorporates pharmacogenomic considerations — including COMT polymorphisms and CYP enzyme variations — into LDN prescribing. This means your dosing strategy isn't based on population averages; it's informed by how your body actually metabolizes and responds to the medication. Integrative oncology: Dr. Kim applies LDN protocols as evidence-based adjunctive therapy in cancer care, drawing on his years leading integrative oncology programs. For clients navigating cancer treatment, this means access to a physician who understands how LDN fits alongside conventional oncology — not in place of it. The endorphin blockade and "feeling worse before better": One of the most common reasons clients abandon LDN prematurely is the paradoxical worsening that can occur as the body adjusts to the temporary endorphin blockade. Dr. Kim actively educates his clients on this mechanism, preparing them for what to expect so they don't mistake an expected adjustment phase for treatment failure. Community leadership: Dr. Kim leads the LDN Support Group, a community of over 9,000 members, and collaborates with organizations like the LDN Research Trust to advance research, education, and advocacy for the therapy. This means his clinical work is continually informed by real-world client experiences across a massive, diverse population of LDN users. Why LDN Demands More Than a One-Time Prescription Complex conditions rarely respond to a fixed dose. A client starting LDN for MCAS may need a dramatically different titration path than someone using it for POTS, pediatric IBD, or as part of an integrative oncology plan. Pharmacogenomic factors, herb-drug interactions, compounding pharmacy quality, and overlapping diagnoses all shape the right starting dose and the pace of adjustment. Without ongoing access to a physician who actually understands these nuances, clients are often left to guess — or to give up before finding their effective dose. This is especially true for LDN, where the "sweet spot" is highly individual. Dr. Kim has developed the Kim LDN Optimal Dose Questionnaire™ — a structured clinical tool designed to help identify each client's ideal dosing range — because he understands that the difference between LDN working and not working is often a matter of milligrams, timing, and patience guided by expertise. How the Membership Model Solves This This is exactly why Dr. Kim's practice, www.directintegrativecare.com, is structured as a membership-based direct care model rather than a traditional fee-for-visit practice. Instead of paying per appointment and hoping your questions fit into a rushed slot, membership gives you: Direct, ongoing access to Dr. Kim for dose adjustments as your body responds — not just at your next scheduled follow-up Continuity of care with one physician who knows your full history, rather than a rotating cast of providers Time for complexity — the kind of unhurried, root-cause conversations that MCAS, POTS, autoimmune disease, CRPS, and oncology support genuinely require A sustainable long-term relationship, including a Maintenance tier for clients who've stabilized and need ongoing prescription continuity without the intensity of active workup Because the practice is capped at a limited number of active clients, doesn't accept insurance, and operates via telemedicine across Texas, Georgia, Florida, Iowa, Illinois, and Missouri, Dr. Kim isn't incentivized to rush visits or churn through volume. The membership structure exists specifically so that clients with complicated, LDN-responsive conditions get the iterative attention this therapy actually demands. What Working With Dr. Kim Looks Like Every LDN relationship starts with a thorough review of your history, prior treatments, labs, and — where appropriate — pharmacogenomic data. From there, Dr. Kim builds a personalized titration plan around your specific condition, goals, and tolerance. Membership means you're never stuck waiting weeks to report a side effect, ask about a compounding pharmacy switch, discuss a ULDN trial, or adjust your dose after a flare. That responsiveness is often the difference between clients who find LDN transformative and clients who give up on it too early. For clients outside Dr. Kim's licensed states or international clients, educational consultations are available to help you understand LDN therapy and work more effectively with your local prescriber. Is This Approach Right for You? If you're managing a complex, chronic condition and have felt like LDN — or integrative medicine in general — deserves more time and attention than conventional care allows, a membership-based relationship may be the structure that finally lets this therapy work the way it's meant to. About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified physician with over 20 years of clinical experience. He completed a fellowship in Integrative Medicine under Dr. Andrew Weil at the University of Arizona and holds certifications in preventive medicine, medical acupuncture, and integrative and holistic medicine. He has served as Medical Director of the Integrative Oncology Program at Miami Cancer Institute and Director of the University of Kansas Medical Center Integrative Medicine Program. Dr. Kim specializes in Low Dose Naltrexone therapy, autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, MCAS, and mold-related illness. He is the author of 3 books — including the LDN Primer and a clinical LDN textbook — and more than 20 peer-reviewed articles. He leads the LDN Support Group (9,000+ members) and collaborates with the LDN Research Trust. Professional site: www.yoonhangkim.com | Clinical practice: www.directintegrativecare.com

Mast Cell Activation Syndrome (MCAS) can feel like navigating a maze with no clear exit. Symptoms vary widely, and traditional treatments sometimes fall short. That’s why I want to share insights into holistic MCAS treatment—an approach that looks beyond symptoms to address the whole person. By combining conventional medicine with lifestyle changes, nutrition, and mind-body techniques, we can find a more balanced path to relief. What Is Holistic MCAS Treatment? Holistic MCAS treatment means treating the entire system, not just the mast cells. Mast cells are immune cells that release chemicals like histamine, causing allergic and inflammatory symptoms. When these cells become overactive, they trigger MCAS, leading to a range of issues such as skin rashes, digestive problems, brain fog, and fatigue. Instead of focusing solely on medications, holistic care explores: Diet and nutrition to reduce triggers and support immune balance Stress management to calm the nervous system Environmental adjustments to limit exposure to irritants Supplements and natural therapies that stabilize mast cells Personalized medical care that targets root causes This approach treats you as a whole person, not just a collection of symptoms. It’s like tuning an orchestra rather than fixing a single instrument. Key Components of Holistic MCAS Treatment When I work with people managing MCAS, I emphasize several pillars that work together: 1. Diet and Nutrition Food can be a major trigger for mast cell activation. A low-histamine diet often helps reduce symptoms. This means avoiding aged cheeses, fermented foods, alcohol, and certain fruits and vegetables that release histamine or block its breakdown. Some practical tips include: Keeping a food diary to identify personal triggers Eating fresh, unprocessed foods Incorporating anti-inflammatory foods like turmeric and ginger Staying hydrated to support detoxification 2. Stress Reduction Stress is a silent amplifier of mast cell activity. Techniques like meditation, deep breathing, yoga, or even gentle walks in nature can lower stress hormones and calm mast cells. Try setting aside 10 minutes daily for mindfulness or breathing exercises. Over time, this can create a buffer against flare-ups. 3. Environmental Control Many environmental factors can worsen MCAS symptoms. These include strong fragrances, mold, dust, and chemical cleaners. Creating a safe, clean living space is essential. Simple steps: Use air purifiers Choose fragrance-free products Regularly clean to reduce dust and mold Avoid exposure to cigarette smoke and harsh chemicals 4. Supplements and Natural Therapies Certain supplements may help stabilize mast cells or reduce inflammation. These include quercetin, vitamin C, and omega-3 fatty acids. However, it’s important to introduce supplements slowly and under guidance, as some can trigger reactions. 5. Personalized Medical Care Working with a healthcare provider who understands MCAS is crucial. They can tailor medications, run appropriate tests, and monitor progress. This personalized approach ensures treatments address your unique triggers and symptoms. By combining these elements, holistic MCAS treatment offers a comprehensive way to regain control and improve quality of life. Is L-theanine a Mast Cell Stabilizer? L-theanine, an amino acid found in green tea, is often praised for its calming effects on the brain. But does it help stabilize mast cells? Research suggests that L-theanine may reduce stress and promote relaxation, which indirectly benefits mast cell stability. Stress triggers mast cell activation, so calming the nervous system can reduce flare-ups. However, L-theanine is not a direct mast cell stabilizer like some medications or supplements such as quercetin. Incorporating L-theanine as part of a stress management routine can be a gentle, supportive tool. For example, sipping green tea or taking L-theanine supplements may help ease anxiety and improve sleep, both important for managing MCAS. How to Start Your Integrative MCAS Journey Starting an integrative treatment plan can feel overwhelming, but breaking it down into manageable steps helps: Track your symptoms and triggers. Use a journal or app to note what worsens or improves your condition. Consult a knowledgeable healthcare provider. They can help design a personalized plan. Begin with diet changes. Try a low-histamine diet and observe how your body responds. Incorporate stress reduction techniques. Even a few minutes daily can make a difference. Evaluate your environment. Make small changes to reduce exposure to irritants. Consider supplements carefully. Introduce one at a time and monitor effects. Remember, progress may be gradual. Patience and consistency are key. If you want to explore more about integrative treatment for mcas, this approach offers a roadmap to lasting relief by addressing the root causes and supporting your body’s natural balance. Embracing a New Path to Wellness Living with MCAS means learning to listen to your body and respond with care. Holistic MCAS treatment is not a quick fix but a journey toward harmony within your immune system and overall health. By combining medical insight with lifestyle changes, you can reduce symptoms and reclaim your life. Think of it as tuning a delicate instrument—each adjustment brings you closer to a clear, beautiful melody. If you’re ready to take the first step, remember that support is available. With the right guidance and a compassionate approach, lasting health transformations are within reach. Thank you for joining me in exploring these integrative strategies. Your health journey is unique, and embracing a holistic approach can open doors to new possibilities.

Direct Integrative Care Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Low Dose Naltrexone (LDN) therapy should only be initiated under the guidance of a qualified healthcare provider. Always consult your physician before starting, stopping, or modifying any treatment. Living with chronic health issues can feel like navigating a maze without a map. You try different treatments, but the relief is often temporary or incomplete. If you have been searching for a specialist who looks beyond symptoms and focuses on the root causes of your condition, Low Dose Naltrexone (LDN) therapy may represent a meaningful turning point—and booking an LDN specialist appointment online can be your first step toward lasting health transformation. At Direct Integrative Care, Dr. Yoon Hang Kim brings over two decades of clinical experience in integrative and functional medicine to every LDN consultation. As the author of two published books on the subject—the LDN Primer, a practical guide for clients and clinicians new to LDN therapy, and LDN for Clinicians, a comprehensive clinical textbook—Dr. Kim is one of the most experienced LDN specialists practicing in the United States today. He is also the founder and administrator of the LDN Support Group, one of the largest online LDN communities with over 9,000 members. Why Choose an LDN Specialist Appointment Online? Finding the right healthcare provider is crucial, especially when dealing with complex chronic conditions. An LDN specialist is trained to use low dose naltrexone as a precision tool to modulate the immune system and reduce chronic inflammation, often with fewer side effects than conventional immunosuppressive medications. But why choose an online appointment? Convenience is a primary advantage. You can schedule your visit from the comfort of your home, fitting it into your busy life without extra travel or waiting rooms. At Direct Integrative Care, telemedicine consultations are available across Iowa, Illinois, Missouri, Texas, Georgia, and Florida, making expert LDN care accessible regardless of your location within these states. Access to genuine expertise matters. Many local providers have limited experience with LDN therapy. An online appointment connects you with a specialist who has deep, published knowledge in this area. Dr. Kim’s clinical experience spans thousands of LDN consultations, and his two books—the LDN Primer and LDN for Clinicians—reflect a level of expertise that is rare in this field. Personalized care is the hallmark of Direct Integrative Care. As a membership-based, insurance-free practice deliberately capped at 99 clients, Dr. Kim offers unhurried consultations that allow time to understand your unique health story and tailor treatments accordingly. This is not a volume-driven model. It is medicine the way it should be practiced—thorough, thoughtful, and focused entirely on you. What to Expect During Your LDN Specialist Appointment Online When you book an LDN specialist appointment online with Direct Integrative Care, the experience is designed to be thorough and supportive. Detailed Health History Review The consultation begins with a comprehensive review of your symptoms, medical history, lifestyle, previous treatments, and relevant laboratory findings. Dr. Kim takes the time to identify the underlying factors contributing to your condition rather than simply cataloging symptoms. This root-cause approach is central to integrative and functional medicine and is the foundation upon which effective LDN therapy is built. Discussion of LDN Therapy You will learn how LDN works, its evidence-based benefits for your specific condition, and what to expect in terms of potential side effects and timelines. Drawing from the clinical frameworks detailed in his books, the LDN Primer and LDN for Clinicians, Dr. Kim will explain why LDN may be an appropriate option for your particular health needs and how it compares with other therapeutic strategies. Personalized Treatment Plan Based on your history and goals, Dr. Kim will create a tailored treatment plan. This may include a carefully calibrated LDN dosing schedule, lifestyle and nutritional recommendations, complementary therapies, and integration with any existing treatments. The goal is a plan that addresses your biology as an individual, not a one-size-fits-all protocol. Follow-Up and Ongoing Support Ongoing monitoring is essential with LDN therapy. Dr. Kim schedules follow-up consultations to assess your response, adjust dosing as needed, and ensure you are progressing toward your health goals. This continuous partnership is a key advantage of the Direct Integrative Care membership model—your specialist knows your case in depth and is accessible when you need guidance. How LDN Works: A Brief Overview LDN is a low dose of naltrexone, a medication originally developed at higher doses for addiction treatment. At low doses, it acts through an entirely different mechanism—one that Dr. Kim describes in detail in both the LDN Primer and LDN for Clinicians. Immune modulation is the central mechanism. LDN helps regulate immune responses, reducing the chronic inflammation that often underlies autoimmune diseases, fibromyalgia, chronic fatigue syndrome, and many other persistent conditions. Rather than suppressing the immune system, LDN encourages balance and self-regulation. Endorphin enhancement is another important effect. LDN temporarily blocks opioid receptors, which triggers an increase in endorphin production. Endorphins are the body’s natural painkillers and mood enhancers, contributing to improved well-being beyond what simple anti-inflammatory medications can achieve. Side effects are generally mild and temporary, owing to the very low doses used. This favorable safety profile makes LDN particularly attractive for clients seeking root-cause solutions who are wary of the side-effect burden of conventional immunomodulatory drugs. Why Choose Dr. Kim as Your LDN Specialist? Not all LDN prescribers are equal. Dr. Kim’s credentials and experience set him apart in several important ways. He is the author of two definitive books on LDN therapy. The LDN Primer provides an accessible yet clinically rigorous introduction for clients and healthcare providers who are new to LDN. LDN for Clinicians is a comprehensive clinical textbook that serves as an authoritative reference for physicians and other prescribers seeking to incorporate LDN into evidence-based practice. Together, these works represent one of the most thorough published treatments of LDN therapy available today. He founded and administers the LDN Support Group, a Facebook community of over 9,000 members that serves as a resource hub for people exploring or actively using LDN therapy. This direct engagement with the LDN community provides Dr. Kim with unparalleled insight into real-world client experiences, common challenges, and emerging clinical patterns. His clinical background includes fellowship training under Dr. Andrew Weil at the University of Arizona, board certifications in both Preventive Medicine and Integrative and Holistic Medicine, UCLA medical acupuncture certification, and IFM Scholar status. He has established integrative medicine programs at major academic medical centers and brings over twenty years of experience in preventive and integrative medicine to every consultation. At Direct Integrative Care, this expertise is delivered through a practice model designed for quality over quantity—a membership-based, insurance-free telemedicine practice where Dr. Kim can devote the time and attention that complex chronic conditions demand. Tips for Preparing for Your Online LDN Consultation To make the most of your appointment, some preparation goes a long way. Gather your recent laboratory results, current medication list, supplement list, and any relevant medical records to share with Dr. Kim. Write down your questions about LDN therapy, potential side effects, and how it fits with your current treatment regimen. Consider keeping a symptom diary in the days before your consultation, tracking symptoms, their frequency, and any identifiable triggers. Choose a quiet, private space for your appointment, and test your internet connection, camera, and microphone ahead of time to ensure a smooth consultation experience. Being prepared helps Dr. Kim use your consultation time efficiently and ensures you receive the most thorough evaluation possible. Taking the Next Step Ready to explore LDN therapy with one of the nation’s leading LDN specialists? Booking an appointment with Direct Integrative Care is straightforward. Visit our fee schedule and services page to learn about membership options, then schedule your consultation online. By choosing Direct Integrative Care, you are investing in a healthcare experience that respects your time, honors the complexity of your condition, and brings genuine published expertise to your care. It is a proactive step toward understanding your body’s needs and unlocking new possibilities for healing. Embracing a New Chapter in Your Health Journey Chronic conditions require more than quick fixes. They call for a thoughtful, integrative approach that addresses the whole person—body, mind, and spirit. Booking an LDN specialist appointment online with Direct Integrative Care is more than scheduling a visit. It is opening a door to a new way of healing, guided by a physician who has literally written the books on this therapy. With expert guidance, personalized treatment, and ongoing support, you can move beyond managing symptoms to achieving lasting health transformation. Take that first step today and discover how LDN therapy might be the key to your well-being. Your health deserves this kind of care—unhurried, comprehensive, and focused on what truly matters: your long-term vitality. About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified physician with over 20 years of experience in preventive and integrative medicine. A graduate of the University of Arizona’s Integrative Medicine Fellowship under Dr. Andrew Weil (Osher Fellow), he holds board certifications in Preventive Medicine and Integrative & Holistic Medicine, UCLA medical acupuncture certification, and IFM Scholar status. Dr. Kim specializes in LDN therapy, autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, MCAS, and mold-related illness. He is the author of three books, including the LDN Primer and LDN for Clinicians, and has published over 20 peer-reviewed articles. Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com

Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Berberine has moved from a centuries-old botanical remedy to one of the most studied supplements in metabolic health. This guide reviews what the evidence actually supports, how berberine works, who may benefit, and — just as importantly — what it cannot do. It is written for readers exploring berberine for a specific health goal and who want a clear, honest, clinically grounded explanation. 1. What Is Berberine? Berberine is a bright-yellow alkaloid found naturally in several plants, including goldenseal (Hydrastis canadensis), barberry (Berberis vulgaris), Oregon grape, and goldenthread (Coptis chinensis). It has been used in Traditional Chinese Medicine and Ayurvedic practice for more than two thousand years, historically for infections, digestive complaints, and fevers. [1][2] In modern integrative and functional medicine, attention has shifted decisively toward metabolic health. Multiple systematic reviews and meta-analyses now support a role for berberine in blood-sugar regulation, lipid management, and weight-related markers. A comprehensive meta-analysis of 46 randomized controlled trials involving 4,158 participants found statistically significant improvements in glycemic control, lipid profiles, BMI, and inflammatory markers compared with controls. [3] It is worth being clear from the outset: berberine remains classified as a dietary supplement in the United States and is not FDA-approved for any medical indication. [4] 2. How Berberine May Affect Metabolism, Blood Sugar, and Lipids The AMPK Pathway Berberine's best-characterized action is the activation of AMP-activated protein kinase (AMPK), an enzyme often described as a cellular “master metabolic switch.” When AMPK is switched on, cells burn more fat, store less of it, and pull more glucose out of the bloodstream. Foundational research published in Diabetes showed that berberine raises AMPK activity in fat and muscle cells, increases GLUT4 translocation (the transporter that moves glucose into cells), and shifts gene expression away from fat creation and toward energy expenditure. [5] Beyond AMPK Berberine's effects are multifactorial. It inhibits mitochondrial respiratory chain complex I, which stimulates glucose breakdown; it suppresses the liver's manufacture of new glucose (a key driver of elevated fasting blood sugar); and it slows carbohydrate absorption in the gut. [6] On the lipid side, it appears to work differently than statins, reducing cholesterol absorption and increasing cholesterol clearance through bile. [7] 3. Specific Potential Benefits Blood Sugar Support Blood-sugar regulation is the most extensively studied application. An early review found berberine comparable to common oral glucose-lowering agents such as metformin and glipizide. [8] The 46-trial meta-analysis reported meaningful reductions in HbA1c, fasting glucose, and post-meal glucose versus control. [3] A large double-blind, placebo-controlled trial across 18 centers in China (the PREMOTE study, 409 newly diagnosed type 2 diabetes patients) confirmed significant HbA1c reduction with berberine and, importantly, identified a gut-microbiome mechanism behind part of that effect. [9] Insulin Sensitivity Support Insulin sensitivity describes how efficiently cells respond to insulin's signal to absorb glucose. Berberine appears to improve it through several routes: enhancing GLUT4 expression, lowering inflammatory cytokine signaling, and protecting pancreatic beta cells. [5][10] Pooled analyses report improvements in fasting insulin and HOMA-IR, two standard measures of insulin resistance. [3] This makes berberine particularly relevant for people working to prevent progression from prediabetes to type 2 diabetes. Cholesterol and Triglyceride Support Berberine has shown consistent, if modest, lipid effects across independent analyses. A meta-analysis of randomized trials found significant reductions in total cholesterol, triglycerides, and LDL cholesterol. [11] A separate analysis examining sex differences found that the HDL benefit may be greater in women than in men. [12] In a placebo-controlled trial, lipid benefits reversed during a washout period and returned when berberine was resumed, suggesting an ongoing rather than cumulative effect. [13] Modest Weight-Management Support Berberine's weight effects are real but modest, and should be framed that way. Systematic reviews report small but significant decreases in body weight and BMI, mainly in people taking more than one gram per day for more than eight weeks. [3] However, the National Center for Complementary and Integrative Health (NCCIH) cautions that many of these studies carried a high risk of bias, that results were inconsistent, and that most participants already had conditions like diabetes or fatty liver. [4] The honest takeaway: berberine may contribute to modest improvement in weight-related markers when metabolic dysfunction is part of the picture. It is not a weight-loss medication. Gut Health and Microbiome Interest Because berberine is poorly absorbed, it stays concentrated in the gut, where it may be especially active. The PREMOTE study identified a specific mechanism: berberine inhibits the bacterium Ruminococcus bromii from transforming bile acids, and this shift correlates with improved blood sugar. [9] Reviews suggest berberine can help reverse microbial imbalance in conditions such as fatty liver disease and type 2 diabetes. [14] One caveat: berberine's antimicrobial action is a double-edged sword, and high doses may suppress some beneficial bacteria. [14] 4. What Berberine Cannot Do It Is Not Equivalent to GLP-1 Medications Berberine is widely marketed as “nature's Ozempic” — a label that is both catchy and misleading. GLP-1 receptor agonists such as semaglutide are prescription drugs that strongly suppress appetite and drive substantial weight loss, on the order of about 15% of body weight in pivotal trials. [15] Berberine does not work this way and is a different category of intervention entirely. It Should Not Replace Prescribed Treatment Berberine is not approved for any medical condition. Anyone managing diabetes, cardiovascular disease, or dyslipidemia with prescribed medication should not reduce or stop those medications in favor of berberine without explicit guidance from their prescriber. Adding berberine on top of glucose-lowering drugs without supervision carries a real risk of hypoglycemia. [4][16] Lifestyle Basics Still Matter No supplement replaces the metabolic benefit of consistent physical activity, a diet that keeps blood-sugar demands moderate, adequate sleep, and stress management. The trials that found benefit were generally conducted alongside — not instead of — these fundamentals. 5. Who Should Consider Berberine, and What to Check First The Best-Fit User Based on available evidence, berberine is most relevant for adults who: Have been told they are prediabetic or have mildly elevated fasting glucose Are working to improve insulin sensitivity as part of a metabolic plan Have borderline-elevated LDL cholesterol or triglycerides Are not pregnant or breastfeeding Are not taking immunosuppressants such as cyclosporine Are not on multiple blood-sugar-lowering medications without supervision It is generally less appropriate as a first-line option for people with established diabetes already on several medications, or for anyone seeking GLP-1-level weight loss. Baseline Testing to Consider Fasting glucose — baseline blood-sugar status HbA1c — the three-month blood-sugar average Fasting lipid panel — total cholesterol, LDL, HDL, triglycerides Fasting insulin and HOMA-IR — to assess insulin resistance where available Blood pressure — berberine may have modest effects, especially with amlodipine [4] Liver enzymes (AST/ALT) — prudent before any metabolic supplement [4] Review Medications Before Use Berberine inhibits several cytochrome P450 enzymes (notably CYP3A4) and P-glycoprotein drug transporters, so it can alter the blood levels of many prescription medications. [17] Key categories to discuss with a pharmacist or physician include: Diabetes medications (metformin, sulfonylureas, insulin) — may amplify glucose-lowering and raise hypoglycemia risk [16] Blood thinners — possible increased bleeding risk Immunosuppressants (cyclosporine) — a well-documented, clinically significant interaction confirmed by NCCIH [4] Blood pressure medications — additive effects are possible Any drug metabolized by CYP3A4 — berberine may raise its blood level [17] Work With a Healthcare Provider Dosing, monitoring, and interaction management are meaningful enough that self-directed use without oversight carries risk. Working with a physician, naturopathic doctor, registered dietitian, or clinical pharmacist provides the context to use berberine appropriately and interpret follow-up labs. At Direct Integrative Care, evaluation of supplements like berberine is always done in the context of a person's full clinical picture and medication list. 6. How to Take Berberine Formats Berberine is most commonly sold as 500 mg capsules or tablets; powders are also available. Because supplement quality is not FDA-regulated, third-party testing (NSF, USP, or equivalent) is worth prioritizing. Newer formulations such as dihydroberberine and berberine phytosome show improved bioavailability in small studies and may allow lower effective doses, though long-term outcome data remain limited. [3] General Use Pattern: Start Low, Assess, Then Adjust Start conservatively — typically 500 mg once daily with the largest meal Assess tolerance for 1–2 weeks — watch for bloating, nausea, or loose stools Increase only if well tolerated — toward 500 mg twice or three times daily if appropriate Divide the dose — never take the full daily amount at once The dose range used in most clinical trials is 1,000–1,500 mg per day, split into two or three doses. [8] Timing Considerations Take berberine with meals — at the start of or during eating. Food enhances absorption, and dividing the dose across meals reduces GI side effects and supports steadier blood levels. Taking it on an empty stomach is not recommended. Some practitioners use a cyclical approach (8–12 weeks on, then a break) to align with trial protocols and observe how biomarkers respond, though there is no firm evidence mandating cycling. Safety Summary Berberine has a generally favorable short-term safety profile in published trials, with no serious adverse events reported in major glycemic and lipid meta-analyses. [3][11] The NIH's LiverTox database reports berberine has not been linked to clinically apparent liver injury in human studies. [4] The primary side effects are gastrointestinal and dose-dependent — nausea, abdominal pain, bloating, diarrhea, and constipation — and are usually manageable by starting low and taking it with food. Firm contraindication: Berberine should not be used during pregnancy, while breastfeeding, or by infants. It can displace bilirubin from albumin, potentially causing or worsening jaundice and increasing the risk of kernicterus (severe, potentially irreversible brain damage) in newborns. This is a contraindication, not a precaution. [4][18] Medical Disclaimer This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. It does not establish a physician–patient relationship. Always consult a qualified healthcare provider before starting any new supplement or making changes to your medications. Individual needs and risks vary. About Dr. Kim Dr. Yoon Hang “John” Kim, MD, MPH is a board-certified physician with more than 20 years of experience in integrative and functional medicine. He completed a fellowship at the University of Arizona under Dr. Andrew Weil (Osher Fellow) and holds board certifications in Preventive Medicine and Integrative/Holistic Medicine. He is a Certified Medical Acupuncturist (UCLA) and an IFM Scholar. Dr. Kim specializes in LDN therapy, autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, CFS/ME, MCAS, and mold toxicity. He is the author of three books and more than 20 articles. Professional site: www.yoonhangkim.com | Clinical practice: Direct Integrative Care References Neag MA, Mocan A, Echeverría J, et al. Berberine: botanical occurrence, traditional uses, extraction methods, and relevance in cardiovascular, metabolic, hepatic, and renal disorders. Front Pharmacol. 2018;9:557. Och A, Podgórski R, Nowak R. Biological activity of berberine — a summary update. Toxins (Basel). 2020;12(11):713. Guo J, Chen H, Zhang X, et al. The effect of berberine on metabolic profiles in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Oxid Med Cell Longev. 2021;2021:2074610. National Center for Complementary and Integrative Health (NCCIH). Berberine and Weight Loss: What You Need To Know. U.S. Department of Health and Human Services; updated 2023. nccih.nih.gov Lee YS, Kim WS, Kim KH, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006;55(8):2256–2264. Yin J, Gao Z, Liu D, Liu Z, Ye J. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab. 2008;294(1):E148–E156. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10(12):1344–1351. Lan J, Zhao Y, Dong F, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipidemia and hypertension. J Ethnopharmacol. 2015;161:69–81. Zhang Y, Gu Y, Ren H, et al. Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). Nat Commun. 2020;11(1):5015. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57(5):712–717. Dong H, Zhao Y, Zhao L, Lu F. The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials. Planta Med. 2013;79(6):437–446. Xu X, Yi H, Wu J, et al. Overall and sex-specific effect of berberine on glycemic and insulin-related traits: a systematic review and meta-analysis. J Nutr. 2023 (and associated dose-response analyses). 20 studies, n≈1,761. Derosa G, Maffioli P, Cicero AFG. Berberine on metabolic and cardiovascular risk factors: placebo-controlled trial with washout/re-challenge design. (Cicero AFG, et al. lipid trials in low-risk subjects.) Zhang L, Wu X, Yang R, et al. Effects of berberine on the gastrointestinal microbiota (review of dysbiosis reversal in NAFLD, hyperlipidemia, and T2DM). Front Cell Infect Microbiol / PMC. 2023. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. RxList / WebMD. Berberine: interactions with antidiabetic medications and hypoglycemia risk. Accessed 2026. Guo Y, Chen Y, Tan ZR, et al. Repeated administration of berberine inhibits cytochrome P450 (CYP3A4, CYP2D6) and P-glycoprotein activity in humans. Eur J Clin Pharmacol. 2012;68(2):213–217. Chan E. Displacement of bilirubin from albumin by berberine. Biol Neonate. 1993;63(4):201–208.

Innovative Integrative Treatments for MCAS: A New Path to Healing Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician For people living with Mast Cell Activation Syndrome (MCAS), the search for relief can feel like chasing a moving target. Symptoms flare unpredictably, span nearly every organ system, and rarely respond to a single medication. The most meaningful progress I have seen in clinical practice does not come from one breakthrough drug — it comes from thoughtfully layering therapies that act on different parts of the mast cell problem at the same time. That integration is the real innovation. This article explains how three complementary approaches — mast cell stabilizers such as ketotifen, low-dose naltrexone (LDN), and sublingual immunotherapy (allergy drops) — can be combined into a coherent, individualized plan. 1. MCAS: A Condition Hiding in Plain Sight In MCAS, mast cells — immune cells that normally defend against threats — become inappropriately reactive and release inflammatory mediators such as histamine, tryptase, prostaglandins, leukotrienes, and cytokines when they shouldn't. The result is a confusing constellation of symptoms: flushing, hives, abdominal pain, diarrhea, brain fog, palpitations, fatigue, and reactions to foods, medications, scents, or temperature changes. Because these symptoms cross so many specialties, patients often spend years without a unifying diagnosis. [1][2] Diagnostic frameworks have matured considerably, including the global “consensus-2” criteria and the AAAAI work group report, which emphasize episodic symptoms in two or more organ systems, evidence of mast cell mediator release, and response to mast-cell-directed therapy. [1][3] MCAS also frequently travels with conditions such as Ehlers-Danlos syndrome and POTS, which is why a whole-person approach matters. [3] I wrote about this hidden epidemic and how patients can advocate for themselves in my book, MCAS: An Epidemic Hiding in Plain Sight — A Patient Empowerment Guide (available on Amazon). The goal of this article is to go a step further and show how innovative, layered treatment actually comes together. 2. Why Single-Agent Approaches Often Fall Short The foundational cornerstone of MCAS management is a robust antihistamine protocol — typically an H1 blocker (such as cetirizine or fexofenadine) paired with an H2 blocker (such as famotidine), often at doses higher than standard over-the-counter use. Combining H1 and H2 blockade is consistently more effective than either alone. [4][5] But antihistamines block only the downstream effects of histamine. Dysregulated mast cells release hundreds of different mediators during a flare, so blocking one of them rarely produces complete or lasting stability. [5] This is the central insight behind integrative MCAS care: lasting relief usually requires addressing the problem at several levels at once — blocking mediators, stabilizing the mast cell so it releases less, calming the upstream immune signals that keep mast cells on high alert, and, where relevant, retraining the immune system away from the allergic sensitization that triggers flares in the first place. 3. The Innovation: Layering Therapies That Work on Different Levels Pillar One — Stabilizing the Mast Cell: Ketotifen Where antihistamines block histamine after it is released, mast cell stabilizers work upstream to keep the cell from degranulating in the first place. Ketotifen is particularly valuable because it does both jobs at once: it is both an H1 antihistamine and a mast cell stabilizer. [6][7] Clinically, it is often especially helpful for itch, skin and gastrointestinal symptoms, and nighttime stability, and many patients tolerate it well when started low and titrated slowly. [6] Oral cromolyn sodium is another stabilizer frequently used for gastrointestinal symptoms, and leukotriene receptor antagonists such as montelukast can add benefit for respiratory and vascular symptoms driven by non-histamine mediators. [4][6] The principle is the same: cover more of the mediator landscape than any single agent can. Pillar Two — Calming the Immune Thermostat: Low-Dose Naltrexone (LDN) Low-dose naltrexone is one of the more compelling tools in integrative mast cell care because it works further upstream than antihistamines or stabilizers. At low doses, naltrexone behaves very differently than it does at the higher doses used for addiction. It appears to act as a glial modulator and an antagonist at Toll-like receptor 4 (TLR4), a pattern-recognition receptor central to innate immune activation — a pathway directly relevant to mast cell biology. [8][9] In laboratory studies, low-dose naltrexone shifts microglia from a pro-inflammatory state toward a quieter, anti-inflammatory phenotype and reduces signaling molecules such as TNF-α, IL-6, and interleukin-1. [9][10] In other words, rather than simply blocking a single mediator, LDN may help turn down the overall inflammatory “thermostat” that keeps mast cells hyper-reactive. It has a long track record of use in related chronic inflammatory and pain conditions and is generally well tolerated, which is why I find it a natural complement to mast cell stabilizers rather than a competitor to them. [11] Pillar Three — Addressing Root Allergic Drivers: Sublingual Immunotherapy (Allergy Drops) For many MCAS patients, underlying allergic sensitization is a major and ongoing trigger. Sublingual immunotherapy (SLIT), commonly known as allergy drops, takes aim at that root driver rather than just masking reactions. Tiny, gradually increasing doses of allergen are placed under the tongue, where specialized immune cells in the oral lining are biased toward tolerance rather than inflammation. [12][13] Over time, SLIT shifts the immune response away from the allergic (Th2) pattern and toward tolerance: it induces IL-10-producing regulatory T cells, promotes protective “blocking” IgG4 antibodies, and reduces allergen-specific IgE. [12][13][14] It is well established and FDA-recognized for IgE-mediated allergic rhinitis and certain food allergies, with a favorable safety profile compared with allergy shots. [15] In an integrative MCAS plan, the logic is to reduce the allergic load that repeatedly provokes mast cells — so that the stabilizers and LDN have less to fight against. Its specific role must be individualized, since SLIT is not a labeled MCAS therapy and is appropriate only when genuine IgE-mediated sensitization is documented. 4. Putting It All Together: The Sequencing Logic Innovation here is not a single new drug — it is the orchestration. A thoughtful, individualized plan generally builds in layers rather than all at once: Establish the foundation — optimize H1/H2 antihistamine coverage and trigger avoidance to create a stable baseline. Add a mast cell stabilizer — introduce ketotifen (and/or cromolyn) to reduce degranulation upstream of histamine release. Calm the immune thermostat — layer in low-dose naltrexone to modulate TLR4 and glial-driven inflammation, started low and titrated. Address root allergic drivers — where IgE-mediated allergy is documented, use sublingual immunotherapy to build tolerance and lower the trigger load over time. Support the foundation continuously — nervous-system regulation, sleep, anti-inflammatory nutrition, and targeted supplements reinforce every other layer. Introducing therapies one at a time, low and slow, is essential in a population that is often exquisitely sensitive. It lets both you and your clinician see clearly what each layer contributes and minimizes the risk of reacting to a new agent or its inactive ingredients. 5. The Foundational Supports That Make Everything Work Better Trigger identification and avoidance — foods, scents, medications, temperature swings, and stress are common provocateurs; a symptom-and-trigger journal is invaluable. A lower-histamine, anti-inflammatory diet — individualized rather than maximally restrictive, to reduce dietary mediator load without compromising nutrition. Nervous-system regulation — because stress activates mast cells directly, practices that calm the autonomic nervous system are genuinely therapeutic, not optional extras. Natural mast cell support — bioflavonoids such as quercetin and luteolin and adequate vitamin C may offer gentle, complementary stabilizing support for some patients. [4] Addressing comorbidities and hidden triggers — evaluating for infections, gut dysbiosis, and conditions like POTS or EDS that travel with MCAS. 6. Working Safely With Your Provider MCAS care is highly individual, and the medications discussed here — ketotifen, LDN, and sublingual immunotherapy — each require professional prescribing, dosing, and monitoring. None should be started or combined without medical supervision, particularly given how reactive many patients are to new agents and fillers. Compounded, dye-free formulations are often better tolerated. At Direct Integrative Care, these therapies are always layered within the context of a person's full history, triggers, comorbidities, and medication list — never as a one-size-fits-all protocol. If you want a deeper, patient-friendly roadmap to understanding and advocating for your own MCAS care, my book MCAS: An Epidemic Hiding in Plain Sight walks through these ideas in greater depth. Medical Disclaimer This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment, and does not establish a physician–patient relationship. MCAS treatment must be individualized. Always consult a qualified healthcare provider before starting, stopping, or combining any medication or supplement. Individual needs, sensitivities, and risks vary. About Dr. Kim Dr. Yoon Hang “John” Kim, MD, MPH is a board-certified physician with more than 20 years of experience in integrative and functional medicine. He completed a fellowship at the University of Arizona under Dr. Andrew Weil (Osher Fellow) and holds board certifications in Preventive Medicine and Integrative/Holistic Medicine. He is a Certified Medical Acupuncturist (UCLA) and an IFM Scholar. Dr. Kim specializes in LDN therapy, autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, CFS/ME, MCAS, and mold toxicity. He is the author of three books and more than 20 articles. Professional site: www.yoonhangkim.com | Clinical practice: Direct Integrative Care References Afrin LB, Ackerley MB, Bluestein LS, et al. Diagnosis of mast cell activation syndrome: a global “consensus-2.” Diagnosis (Berl). 2021;8(2):137–152. Molderings GJ, Brettner S, Homann J, Afrin LB. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol. 2011;4:10. Weiler CR, Austen KF, Akin C, et al. AAAAI Mast Cell Disorders Committee Work Group Report: mast cell activation syndrome (MCAS) diagnosis and management. J Allergy Clin Immunol. 2019;144(4):883–896. Valent P, Akin C, Bonadonna P, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. J Allergy Clin Immunol Pract. 2019;7(4):1125–1133. Cardet JC, Castells MC, Hamilton MJ. Immunology and clinical manifestations of non-clonal mast cell activation syndrome. Curr Allergy Asthma Rep. 2013;13(1):10–18. (H1/H2 combination and multi-mediator rationale.) Afrin LB. Presentation, diagnosis, and management of mast cell activation syndrome. In: Mast Cells: Phenotypic Features, Biological Functions and Role in Immunity. Nova Science; 2013. (Ketotifen and cromolyn dosing/role.) Grant SM, Goa KL, Fitton A, Sorkin EM. Ketotifen: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders. Drugs. 1990;40(3):412–448. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. Cant R, Dalgleish AG, Allen RL. Naltrexone inhibits IL-6 and TNFα production in human immune cell subsets following stimulation with ligands for intracellular toll-like receptors. Front Immunol. 2017;8:809. Toljan K, Vrooman B. Low-dose naltrexone (LDN) — review of therapeutic utilization. Med Sci (Basel). 2018;6(4):82. (Microglial/TLR4 immunometabolic modulation.) Srinivasan A, et al. Real-world effectiveness and tolerability of low-dose naltrexone for chronic pain and inflammatory conditions, including MCAS and hypermobility spectrum disorders. J Pain Res. 2025. (Clinical use in MCAS-related populations.) Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ J. 2015;8(1):17; and Akdis M. Immunological mechanisms of sublingual immunotherapy. Allergy. 2006;61(Suppl 81):11–14. Moingeon P. Update on immune mechanisms associated with sublingual immunotherapy: practical implications for the clinician. J Allergy Clin Immunol Pract. 2013;1(3):228–241. Sublingual immunotherapy induces IL-10-producing regulatory T cells, IgG4 “blocking” antibodies, and reduced allergen-specific IgE: reviewed in Immunotherapy Adv. 2022;2(1):ltac022. Greenhawt M, Oppenheimer J, Nelson M, et al. Sublingual immunotherapy: a focused allergen immunotherapy practice parameter update. Ann Allergy Asthma Immunol. 2017;118(3):276–282.

Hope: A Biological Imperative for Chronic Illness Recovery Hope isn't a luxury for people living with chronic illness — it's a biological imperative. But before we can understand why, we need to dismantle a persistent misconception: that positive psychology is simply the academic dressing on "think happy thoughts." It isn't. Not even close. Positive psychology, as defined within the Handbook of Positive Psychology framework, is the rigorous scientific study of what allows individuals and communities to thrive. Martin Seligman, widely credited with formalizing the field, made a deliberate pivot away from psychology's historically deficit-based model — one obsessed with pathology, disorder, and dysfunction — toward a strength-based approach that asks a fundamentally different question: What makes life worth living, even when it's hard? Understanding Well-Being: Hedonic vs. Eudaimonic A concept central to that question is the distinction between two types of well-being: Hedonic well-being — fleeting pleasure, the momentary absence of pain Eudaimonic well-being — meaning, purpose, and authentic engagement with life For someone experiencing physical suffering, hedonic well-being is often simply out of reach. Research confirms that chronic illness relentlessly erodes moment-to-moment comfort. Eudaimonic well-being, however, remains accessible — and that distinction is clinically significant. A useful positive psychology an introduction summary of this framework would be: stop measuring health only by what's broken. Start building what's working. Positive psychology isn't passive. It's a set of evidence-informed interventions — including nervous system regulation techniques, meaning-making practices, and resilience-building tools — that directly influence biological outcomes. That biological connection is exactly where the next piece of this puzzle begins. The Functional Medicine Link: How Mindset Regulates the Nervous System Here's something most treatment plans miss entirely: you can take every supplement, follow every elimination diet, and work with the best specialists in the country — and still plateau. Why? Because if your nervous system is locked in a chronic stress response, your body is physiologically resistant to healing. The Problem of Sympathetic Dominance Chronic illness doesn't just cause suffering — it perpetuates it. Pain, fatigue, unpredictability, and loss of function are powerful triggers for the body's sympathetic nervous system, keeping it in a near-constant state of fight-or-flight. This state of sympathetic dominance floods the body with cortisol and adrenaline, suppresses immune regulation, and — critically — drives the production of pro-inflammatory cytokines like IL-6 and TNF-alpha. In other words, the stress of being sick makes the underlying biology of illness worse. This isn't a minor side effect. It's a central mechanism. Where Positive Psychology Enters the Clinical Picture Positive psychology for chronic illness is not about mood management. It's about nervous system regulation. When a person consistently engages in evidence-based practices — structured meaning-making, cultivating positive affect, or building social connection — they activate the parasympathetic nervous system, often called the "rest and digest" state. Research published in Positive Psychology and Physical Health confirms that positive emotional states are directly associated with downregulated inflammatory markers and improved immune function. A nervous system stuck in survival mode cannot prioritize repair. That's not a metaphor — it's basic autonomic biology. The Functional Medicine Blind Spot Functional medicine practitioners spend enormous energy addressing gut permeability, hormonal dysregulation, and autoimmune triggers. But as research from IntechOpen on chronic illness recovery highlights, psychological and physiological systems are deeply interdependent. Treating one while ignoring the other produces limited, frustratingly temporary results. The practical implication is clear: psychological interventions are upstream regulators of physical health outcomes. Which brings us to the most well-researched entry point into that regulation — and it starts with something as simple as gratitude. Practice 1: Gratitude as a Survival Mechanism for the Immune System Gratitude isn't a greeting card sentiment. For people managing chronic illness, it's a measurable physiological tool — and the research behind it is harder to ignore than most clinicians realize. Research published in Positive Psychology and Physical Health links higher levels of positive affect — including gratitude — to reduced mortality risk and better immune regulation. That's not a minor footnote. That's a clinical argument for treating gratitude as part of a recovery protocol. The 'Broaden and Build' Theory in Practice Psychologist Barbara Fredrickson's Broaden and Build theory offers a compelling explanation for why this happens. Positive emotions — even brief, small ones — don't just feel good. They temporarily expand our cognitive flexibility and physical repertoire, building lasting psychological and biological resources over time. For someone managing a chronic condition, this means gratitude isn't passive; it's actively reconstructing capacity. This is where functional medicine brain health intersects directly with emotional practice. A nervous system primed by repeated positive emotional states is a nervous system better equipped to regulate inflammation and immune response. The Negativity Bias Problem — and the Micro-Habit Fix Chronic illness amplifies the brain's natural negativity bias. When pain is persistent, the mind defaults to threat-scanning — cataloging what's wrong, what's worsening, what's lost. A sustainable micro-habit: Each evening, identify one thing your body did manage today — not what it failed to do. Even on a flare day, the lungs breathed. The heart kept rhythm. This single reframe, practiced consistently, begins to rewire threat-dominant neural patterns toward something more balanced. Gratitude, practiced deliberately, is one of the lowest-cost, highest-impact interventions available to someone whose body is already under siege. Of course, emotional practices don't happen in isolation — and neither does healing. What surrounds us matters just as much as what we think. That leads directly to the next powerful physiological lever: social connection. Practice 2: Social Connection as a Physiological Buffer Gratitude shifts your internal chemistry. But connection? Connection changes what your body can survive. Research consistently shows that strong social ties directly influence antiviral immune responses. Loneliness activates what scientists call the Conserved Transcriptional Response to Adversity (CTRA) — a gene-expression pattern that suppresses antiviral defenses while ramping up inflammatory activity. In practical terms, chronic isolation doesn't just feel bad. It makes your immune system measurably less equipped to fight back. This is a core reason why understanding why mindset is important for chronic illness recovery extends beyond attitude — it reaches into your cellular biology. The contrast is stark. Research published in positive psychology literature highlights that social support acts as a genuine physiological buffer, moderating stress hormone output and improving treatment adherence over time. Strong social bonds aren't a comfort measure — they're a clinical one. However, chronic illness creates a cruel paradox here. Fatigue, pain flares, and unpredictable symptoms make traditional socializing genuinely difficult. Canceling plans repeatedly can trigger guilt, which further compounds isolation. The solution isn't forcing yourself into exhausting social settings. Low-energy connection strategies preserve relationships without depleting your limited reserves: Slow texting: Responding at your own pace, no pressure for real-time conversation Shared streaming: Watching the same show simultaneously with a friend, connected via chat Voice memos: More intimate than text, less demanding than a phone call Online illness communities: Spaces where your experience is immediately understood What emerges from consistent, intentional connection — however small — sets the foundation for the structured daily practices covered next. Practical Implementation: Your Daily Positive Psychology Protocol Gratitude and connection reshape your physiology over time. But how do those principles translate into actual daily habits to support functional medicine treatment? Here's a concrete protocol — built on evidence, not inspiration posters. The 'Three Good Things' Exercise, Adapted for Health Wins The original exercise asks you to record three positive events each day. For chronic illness, it works best when you narrow the lens. Note three health-related wins, however small: a symptom that eased by mid-afternoon, completing a short walk, eating a meal without distress. Research on positive psychology interventions consistently shows that directing attention toward progress — even incremental progress — reinforces the neural pathways associated with motivation and resilience. Five minutes before bed is enough. Brief Mindfulness for Acute Symptom Management When a flare hits, the nervous system compounds the problem. A two-minute physiological reset can interrupt that cycle. One practical approach is box breathing: inhale for four counts, hold for four, exhale for four, hold for four. Repeat four times. This directly activates the parasympathetic nervous system, reducing inflammatory signaling triggered by the stress response. It doesn't eliminate pain — but it removes the layer of panic that amplifies it. Identifying Signature Strengths to Reclaim Identity Chronic illness narrows identity. Over time, "patient" becomes a primary role, which research on wellbeing in chronic conditions links to poorer outcomes. Signature Strengths — creativity, humor, curiosity, leadership — exist independently of your diagnosis. Identifying and using at least one strength daily rebuilds a sense of agency that illness routinely erodes. A consistent identity outside of illness is not a luxury — it's a measurable predictor of recovery trajectory. Tracking Psychology Alongside Physical Symptoms Keep a simple dual log: rate one physical symptom (pain, fatigue, digestion) and one psychological metric (mood, sense of agency, connection) on the same scale, daily. Patterns will emerge. That correlation is data — the kind worth bringing to your next clinical appointment. These aren't standalone strategies. They're inputs into a larger recovery system — and how they integrate with your broader treatment plan is exactly what the next section addresses. Key Nervous System Regulation Techniques Takeaways Hedonic well-being — fleeting pleasure, the momentary absence of pain Eudaimonic well-being — meaning, purpose, and authentic engagement with life Slow texting: Responding at your own pace, no pressure for real-time conversation Shared streaming: Watching the same show simultaneously with a friend, connected via chat Voice memos: More intimate than text, less demanding than a phone call Conclusion: Integrating Brain Health into Your Recovery Roadmap Chronic illness recovery is biological work. But biology doesn't happen in a vacuum — it happens inside a nervous system that is constantly shaped by your thoughts, relationships, and daily habits. That's the central argument running through everything covered here, and it deserves a final, clear statement: mindset is a clinical tool, not a motivational add-on or a replacement for medical care. Think of it as a Golden Thread woven through every layer of your recovery. Nervous system regulation — achieved through gratitude practices, social connection, and intentional daily rituals — creates the physiological conditions in which physical healing becomes more possible. Reduced cortisol, lower systemic inflammation, improved immune signaling: these aren't metaphors. They're measurable outcomes documented in peer-reviewed research, including work referenced in the handbook of positive psychology literature and applied frameworks explored in transforming health care with applied positive psychology. Small, consistent psychological shifts produce measurable biological change over time. You don't need a dramatic overhaul. You need a protocol — practiced daily, adjusted thoughtfully, and supported by qualified guidance. If you're navigating chronic illness and want to build a recovery plan that treats your brain health as seriously as your physical health, the next step is a conversation. Schedule a consultation today to explore a holistic recovery roadmap built around your specific biology, your goals, and the science of what actually heals.

Yoon Hang “John” Kim, MD, MPH, FAAMA Board-Certified Preventive Medicine | Integrative & Functional Medicine | LDN Research Trust Presenter The short version If you’ve been told LDN will make you better but every dose so far has made you worse, you aren’t broken and you aren’t a “bad responder.” You may be a canary patient — exquisitely sensitive, with a depleted endorphin reserve.For canary patients, the standard 1.5 → 4.5 mg climb is too much, too fast. The fix isn’t abandoning LDN; it’s starting much lower (sometimes in micrograms or nanograms) and moving much more slowly. This piece walks you through how I think about it in clinic. I’ve been prescribing low dose naltrexone (LDN) for over two decades. In that time, I’ve learned that the patients who do worst on standard protocols are often the ones who need LDN the most. They typically present with mast cell activation syndrome (MCAS), myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), long-standing autoimmune disease, or histories of mold or Lyme exposure, post-viral illness, or some combination. These are the canaries. And like the canaries miners once carried into coal shafts, their bodies are picking up on something the rest of the room doesn’t feel yet. That sensitivity is information. The clinical task is to honor it. Who is a “canary” patient? “Canary” isn’t a formal diagnosis. It’s a description of a clinical pattern I see all the time. Canary patients tend to share most of the following: Years (often decades) of complex, layered illness rather than a single recent diagnosis. Multiple drug or supplement intolerances — they react to things other patients tolerate without a thought. A pattern of paradoxical reactions: small doses cause big symptoms; “starter” doses feel like overdoses. MCAS features (flushing, hives, food and odor sensitivities, GI symptoms, dysautonomia). Post-exertional malaise — even mild activity is followed by a crash, often delayed by a day or two. A profound loss of resilience — colds linger, stressors don’t bounce off, sleep doesn’t restore. What ties these features together, in my view, is a depleted endorphin reserve. The body has been running on emergency reserves for so long that it has very little buffer left. Introducing anything that touches the opioid system — even a small dose of LDN — can feel destabilizing. Understanding the Endorphin Reserve Endorphins are your body’s own opioid-like chemicals. They help with pain, mood, sleep, immune balance, and resilience under stress. Think of them as the vitality currency your nervous system spends every day. When you’re healthy, the account refills overnight. When you’ve been ill for a long time, you’re running an overdraft. In Traditional Chinese Medicine this kind of deep reserve is called Jing. In Ayurveda it’s Ojas. Different languages, the same idea: a measurable-by-feel sense of how much vital capacity you have left in the tank. LDN works in part by encouraging your body to make more of its own endorphins and to use them more effectively. That’s wonderful for a patient with reasonable reserves to start with. For a canary patient with very little reserve, the same nudge can feel like running an engine that’s already overheating. This is why I almost never start a canary patient at 1.5 mg. Often, I start a hundred times lower, sometimes a thousand times lower. The goal isn’t a “bigger” dose — it’s the smallest dose that wakes up the system without overwhelming it. The Kim LDN Optimal Dose Questionnaire™ Before prescribing the first dose, I ask every patient five questions. I’ve refined this in clinic over many years, and I now call it the Kim LDN Optimal Dose Questionnaire™. It’s not a lab test. It’s a structured way of estimating how much endorphin reserve you have to work with — and therefore where to start. # Question What I’m listening for 1 How long have you been sick? Decades of illness suggest deeper reserve depletion than a recent diagnosis. 2 Do you wake up restored? Non-restorative sleep is one of the loudest markers of depleted endorphin function. 3 What is your energy like across a normal day? Crashes, post-exertional malaise, and an inability to “push through” all point to low reserve. 4 How quickly do you bounce back from setbacks (an infection, a stressor, a bad week)? Slow recovery from ordinary insults is a resilience problem, not a willpower problem. 5 Can you still work, exercise, parent, or run your daily life? Functional capacity is the practical, day-to-day proxy for endorphin reserve. I’m not assigning a numerical score. I’m listening to the texture of the answers. A patient who has been ill for fifteen years, sleeps poorly, runs on caffeine to make it to lunch, and crashes for three days after a short walk. Stopped working two years ago is in an entirely different place from a patient with a recent autoimmune diagnosis who still hikes on the weekends. Both may benefit from LDN. They should not start at the same dose. Start-low-go-slow: Titration Tables for Canary Patients Most LDN information online describes a fast climb to 4.5 mg over two to four weeks. That’s a reasonable starting point for a more robust patient. For a canary patient, it can be a setup for a flare. Below is how I actually think about the dose ladder. Table 1. The LDN Dose Ladder Category Dose range Who it tends to fit Standard LDN 1.5 – 4.5 mg (sometimes up to 10 mg) A patient with reasonable energy and resilience, a clear diagnosis, and no history of paradoxical drug reactions. Very-low-dose (VLDN) 0.01 – 0.5 mg A patient who can usually tolerate medications but has been sick a long time, or has had side effects on a typical starting dose. Ultra-low-dose (ULDN) 1 – 100 micrograms (mcg) Most canary patients land here: MCAS, ME/CFS, long-standing autoimmune disease, post-viral illness, mold/Lyme. Nanogram dosing Below 1 mcg, in the nanogram range Reserved for the most sensitive patients who react even at 1 mcg. Requires specialty compounding or careful self-dilution. At 1 microgram, naltrexone barely tickles the opioid system. It can still act as a hormetic signal. A small biological nudge that asks the body to make more endorphins without overwhelming the receptors it’s trying to support. Table 2. Where I Start, and How Slowly I Climb Patient picture Starting dose How often I increase Standard patient, moderate illness 1.5 mg Toward 4.5 mg over 2 – 4 weeks. Severely ill or low functional capacity 0.5 mg or lower Every 2 – 4 weeks, in small steps. Canary patient (MCAS, ME/CFS, complex autoimmune) 10 mcg – 100 mcg Every 4 weeks or longer; some patients need 6 – 12 weeks between increases. Extreme sensitivity (reactions at 1 mcg) Nanogram range Every 1 – 3 months. Patience is the medicine. Children Microgram dosing Very slow, individualized titration. Side effects appear at any dose Drop back to the last well-tolerated dose Hold longer before trying to advance again. Two practical points families ask me about1. Compounding matters. Microgram and especially nanogram doses are not standard pharmacy stock. They require a compounding pharmacy that is genuinely comfortable working at this level. If your pharmacy hesitates, find one that doesn’t.2. Liquid is usually easier than capsules at this level. Liquid LDN lets us make small, precise changes without re-ordering capsules every week. For very sensitive patients, this flexibility is the difference between staying on therapy and quitting in frustration. What the Science Actually Says (The Honest Version) LDN is one of my favorite tools. It is not magic. Anyone selling it as a sure thing is overselling. On the encouraging side, the early fibromyalgia studies by Younger and colleagues at Stanford showed about a 29% reduction in pain on 4.5 mg of LDN compared to roughly 18% on placebo. A retrospective analysis at the Mayo Clinic of 115 patients found that about 65% of those on LDN for chronic pain reported some benefit. In ME/CFS, a retrospective analysis from Finland of 218 patients reported that nearly three-quarters experienced a positive response to 3.0–4.5 mg LDN over an average follow-up of about 1.7 years. On the sobering side, the FINAL trial published in Lancet Rheumatology in 2024. The largest randomized controlled trial of LDN in fibromyalgia to date — did not show a statistically significant pain reduction over placebo at 6 mg. A larger proportion of patients on LDN achieved at least a 30% pain reduction than on placebo, and memory symptoms improved, but the primary endpoint was negative. That deserves to be said out loud, not hidden in a footnote. Two truths can sit side by side. Some patients respond beautifully to LDN. Roughly one in three patients does not respond to standard protocols at all. The canary population sits right at that fault line — which is exactly why dose strategy matters so much. What This Looks Like by Condition Mast Cell Activation Syndrome (MCAS) MCAS patients are often the most reactive of all. In a published BMJ case report, a severely affected patient with both POTS and MCAS could not tolerate ordinary LDN escalation. Her physician started her at 1 mg at night rather than climbing to 4.5 mg. That ultra-low dose improved her pain, mood, sleep, flushing, and food and odor sensitivities. Limb tingling — and became a core part of a regimen that returned her to a near-normal life. In my own practice, almost every MCAS patient starts in the microgram range. We usually pair LDN with a true mast cell stabilization plan (a clean low-histamine baseline, ketotifen, cromolyn, sometimes methylene blue with metabolic support), as I describe more fully in the LDN Primer. LDN by itself is rarely enough; LDN inside a thoughtful MCAS protocol is often transformative. Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) ME/CFS patients almost always have profound post-exertional malaise. They cannot afford to “push through” an LDN side effect. If a 1.5 mg starting dose causes vivid dreams, insomnia, or a flare, they may be set back for weeks. Research from Cabanas, Marshall-Gradisnik, and colleagues at the National Centre for Neuroimmunology and Emerging Diseases has shown that naltrexone may help restore impaired ion channel function (TRPM3) in natural killer cells from ME/CFS patients. That gives a plausible biological reason behind the clinical signal Polo and colleagues reported in their 218-patient series. It also tells us we’re working on a delicate system. Slow titration honors that. Autoimmune Disease For autoimmune patients — Hashimoto’s, lupus, rheumatoid arthritis, multiple sclerosis, Crohn’s disease, psoriasis. Others — LDN’s appeal is its capacity to calm immune dysregulation without the side-effect burden of conventional immunosuppression. Small randomized trials have suggested quality-of-life benefits in MS, and a placebo-controlled trial in active Crohn’s disease showed improvement in mucosal healing on LDN. Autoimmune patients who are otherwise functional often tolerate standard 1.5 → 4.5 mg titration well. Autoimmune patients with overlapping MCAS, ME/CFS, mold, or Lyme histories almost never do. The same diagnosis can hide two very different metabolic situations. That’s why the questionnaire matters more than the diagnostic label. What You Should Expect on a Canary-Patient Protocol It will feel slow. That is the protocol working, not the protocol failing. A canary protocol can take three to six months to find a stable, effective dose, sometimes longer. Vivid dreams and short-term sleep changes are common, even at very low doses, and usually settle. Nightmares in patients with significant trauma history are a reason to pause and reassess. Symptoms may flutter before they improve. Mast cell symptoms, fatigue, or pain can wobble in the first few days after each dose change. If you feel worse and it doesn’t resolve in a few days, the answer is almost always to step down, not to power through. Drop to the last well-tolerated dose and stay there. Roughly a third of patients won’t respond meaningfully to LDN at any dose. If you’re in that group, you’re not failing the medicine — the medicine is showing you that the work is somewhere else. LDN is a Tool, Not the Whole Toolbox Canary patients almost never get fully well on LDN alone. In my experience, LDN often does what nothing else has done — it lowers the noise enough that other treatments finally have a chance to work. That might mean mast cell stabilization, a careful look at mold or Lyme, mitochondrial and metabolic support, hormone balance, sleep repair, trauma-informed nervous-system work. Whatever your particular root causes turn out to be. If you’d like the longer version of this framework — including the dosing categories, how I assess endorphin reserve in detail, when to consider higher-dose naltrexone. The MCAS stacking protocol — it lives in the free LDN Primer at the Low Dose Naltrexone Support Group, and is expanded with case material in my book Low Dose Naltrexone: Two Decades of Clinical Observation and Review of Current Research. Bottom line for canary patientsYou are not too sensitive. You are accurately sensitive. Standard protocols were not designed with you in mind.The right starting dose for you is probably much lower than the internet suggests, and the right pace is much slower.Work with a clinician who knows how to dose in micrograms and nanograms, who can compound or refer to a pharmacy that can, and who will be patient with you while your system relearns how to rest. About the Author Yoon Hang “John” Kim, MD, MPH, FAAMA is a board-certified preventive medicine physician practicing integrative and functional medicine. He completed Dr. Andrew Weil’s Integrative Medicine Fellowship at the University of Arizona and is an Institute for Functional Medicine Certified Practitioner. Dr. Kim has prescribed LDN since the early 2000s, has presented at multiple LDN Research Trust conferences, and has authored three books on LDN. He sees patients via telemedicine through Direct Integrative Care in Iowa, Illinois, Missouri, Georgia, Florida, and Texas, and in person at Hill Country Integrative Medicine in Fredericksburg, Texas. Clinical practice: directintegrativecare.com Physician mentoring: yoonhangkim.com References Bruun, K. D., Christensen, R., Amris, K., Vaegter, H. B., Blichfeldt-Eckhardt, M. R., Bye-Møller, L., Holsgaard-Larsen, A., & Toft, P. (2024). Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: A randomised, double-blind, placebo-controlled trial. The Lancet Rheumatology, 6(1), e31–e39. https://doi.org/10.1016/S2665-9913(23)00278-3 Cabanas, H., Muraki, K., Balinas, C., Eaton-Fitch, N., Staines, D., & Marshall-Gradisnik, S. (2019). Validation of impaired transient receptor potential melastatin 3 ion channel activity in natural killer cells from chronic fatigue syndrome/myalgic encephalomyelitis patients. Molecular Medicine, 25(1), 14. https://doi.org/10.1186/s10020-019-0083-4 Cabanas, H., Muraki, K., Eaton-Fitch, N., Staines, D. R., & Marshall-Gradisnik, S. (2021). Potential therapeutic benefit of low dose naltrexone in myalgic encephalomyelitis/chronic fatigue syndrome: Role of transient receptor potential melastatin 3 ion channels in pathophysiology and treatment. Frontiers in Immunology, 12, 687806. https://doi.org/10.3389/fimmu.2021.687806 Driver, C. N., & D’Souza, R. S. (2023). Efficacy of low-dose naltrexone and predictors of treatment success or discontinuation in fibromyalgia and other chronic pain conditions: A fourteen-year, enterprise-wide retrospective analysis. Biomedicines, 11(4), 1087. https://doi.org/10.3390/biomedicines11041087 Kim, Y. H. (2025). Low dose naltrexone: Two decades of clinical observation and review of current research. Parkitny, L., & Younger, J. (2017). Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines, 5(2), 16. https://doi.org/10.3390/biomedicines5020016 Polo, O., Pesonen, P., & Tuominen, E. (2019). Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Fatigue: Biomedicine, Health & Behavior, 7(4), 207–217. https://doi.org/10.1080/21641846.2019.1692770 Sharafaddinzadeh, N., Moghtaderi, A., Kashipazha, D., Majdinasab, N., & Shalbafan, B. (2010). The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: A randomized placebo-controlled trial. Multiple Sclerosis Journal, 16(8), 964–969. https://doi.org/10.1177/1352458510366857 Smith, J. P., Bingaman, S. I., Ruggiero, F., Mauger, D. T., Mukherjee, A., McGovern, C. O., & Zagon, I. S. (2011). Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn’s disease: A randomized placebo-controlled trial. Digestive Diseases and Sciences, 56(7), 2088–2097. https://doi.org/10.1007/s10620-011-1653-7 Toljan, K., & Vrooman, B. (2018). Low-dose naltrexone (LDN) — Review of therapeutic utilization. Medical Sciences, 6(4), 82. https://doi.org/10.3390/medsci6040082 Weinstock, L. B., Brook, J. B., Myers, T. L., & Goodman, B. (2018). Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. BMJ Case Reports, 2018, bcr-2017-221405. https://doi.org/10.1136/bcr-2017-221405 Younger, J., & Mackey, S. (2009). Fibromyalgia symptoms are reduced by low-dose naltrexone: A pilot study. Pain Medicine, 10(4), 663–672. https://doi.org/10.1111/j.1526-4637.2009.00613.x Younger, J., Noor, N., McCue, R., & Mackey, S. (2013). Low-dose naltrexone for the treatment of fibromyalgia: Findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis & Rheumatism, 65(2), 529–538. https://doi.org/10.1002/art.37734 Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology, 33(4), 451–459. https://doi.org/10.1007/s10067-014-2517-2 Disclaimer. This article is educational and reflects Dr. Kim’s clinical experience and reading of the published literature; it is not medical advice and does not create a physician–patient relationship. LDN dosing — and especially microgram or nanogram dosing — should be guided by a clinician who knows your full history. Read more Key Takeaways Years (often decades) of complex, layered illness rather than a single recent diagnosis. Multiple drug or supplement intolerances — they react to things other patients tolerate without a thought. A pattern of paradoxical reactions: small doses cause big symptoms; “starter” doses feel like overdoses. MCAS features (flushing, hives, food and odor sensitivities, GI symptoms, dysautonomia). Post-exertional malaise — even mild activity is followed by a crash, often delayed by a day or two.

Looking for a Functional Medicine Doctor in San Antonio? Here's How I Work — From Anywhere in Texas Many patients experience the frustration of pursuing symptom relief for years, moving from one specialist to another, only to receive more prescriptions without real solutions. I am Dr. Yoon Hang "John" Kim, specializing in integrative and functional medicine for complex cases often overlooked by standard practices in San Antonio. My practice operates virtually. I provide care to patients in San Antonio, Houston, Austin, Dallas–Fort Worth, the Rio Grande Valley, and every small town in between, as well as those in Iowa, Illinois, Missouri, Georgia, and Florida. You can consult with me through secure video from the convenience of your home, office, or even your car during a lunch break, eliminating the need for travel and waiting rooms. What "Functional Medicine" Actually Means in My Practice Functional medicine refers to a holistic approach that seeks to treat the whole person and identify the root causes of health issues. While these descriptions are accurate, they often lack detail. In my practice, root-cause medicine involves examining underlying systems such as the gut and microbiome, mitochondrial energy production, and immune regulation. I assess factors like toxic exposures and nervous-system patterns that may be contributing to symptoms. For instance, what appears as "depression" might actually be a thyroid issue, or "IBS" could be small intestinal bacterial overgrowth linked to an undiagnosed mast cell activation syndrome. I hold board certification in preventive medicine and completed Dr. Andrew Weil's integrative medicine fellowship at the University of Arizona in 2004. As an Institute for Functional Medicine Certified Practitioner, I've been prescribing low-dose naltrexone since the early 2000s, frequently presenting for the LDN Research Trust, and authoring books on the topic. This background suits the needs of patients whose conditions often puzzle other doctors. Why Virtual Functional Medicine Works — Especially for the Patients I Treat Can functional medicine be effectively practiced through video consultations? For my patients, the answer is "better than in person, most of the time." Here's why: Key Insights Travel challenges for the sickest patients. Conditions like ME/CFS, Long COVID, MCAS, and severe fibromyalgia make clinic visits physically taxing. Virtual consultations remove this barrier, enabling access to necessary care. The essence of visits: conversation and reasoning. Functional medicine primarily involves thorough history taking and reasoning, easily translated to video consultations. While physical exams matter, the core diagnostic work rests in the history and lab results. Convenience of local labs and imaging. I collaborate with Quest, LabCorp, and specialty labs (DUTCH, GI-MAP, mycotoxin panels) for local testing. Patients can have blood drawn at nearby facilities. Medications are sent to local pharmacies, or for LDN and other specialized compounds, to trusted compounding pharmacies. Continuous access between visits. Membership patients can contact me securely between appointments, ensuring ongoing support and communication. The Conditions I See Most Often Common patterns in my practice include: Low-dose naltrexone (LDN) candidates such as fibromyalgia, autoimmune diseases, chronic pain, Long COVID, MCAS, and ME/CFS. Mast cell activation syndrome (MCAS), viewed as an immune derangement syndrome resulting from cumulative stressors. Post-viral conditions like ME/CFS, Long COVID, and related fatigue syndromes, aligned with Society for Integrative Oncology guidelines. Menopausal hormone therapy, often utilizing DUTCH testing to assess estrogen metabolism accurately. Mold toxicity, chronic Lyme, gut/SIBO, stubborn autoimmune diseases. For straightforward cases like sinus infections or routine checkups, primary care doctors or urgent care services are more appropriate. My practice is designed for cases unresponsive to typical treatments. Will Insurance Pay for This? The honest answer is no. My practice is membership-based and direct-pay. I do not bill insurance, and I limit my patient panel to 99 for personalized attention, allowing for communication by message or video between appointments. Important Considerations Membership is managed through Hint.com. While lab work and imaging are ordered through insurance, many patients use FSA or HSA funds for membership fees and visits. We ensure transparency about costs before you commit, so there are no surprises. I chose this model because the insurance-billing system does not align with my practice philosophy. I value the ability to conduct thorough evaluations, use a blend of conventional and integrative methods, and dedicate significant time to each patient, which is only feasible outside the traditional billing system. If You Want to Start Begin with an initial consultation. Gather your medical records, particularly recent lab work, a list of symptoms with timelines, and current medications and supplements. I'll review everything. The first meeting is a detailed conversation to map out known and unknown factors, identify necessary tests, and create a personalized treatment plan. This plan often includes nutrition, targeted supplements, prescription medications when appropriate, and lifestyle modifications tailored to you. Quick fixes aren't promised, but thorough evaluation and dedicated care are guaranteed. If you're in San Antonio, elsewhere in Texas, or in Iowa, Illinois, Missouri, Georgia, or Florida, visit www.directintegrativecare.com to learn more and book an appointment. Key Takeaways Taking Action Convenience of local testing. I order labs through Quest, LabCorp, or specialty providers, with sample collection done locally. Local pharmacy prescriptions. Medications, including LDN and compounded options, are sent to pharmacies I've worked with for years. Accessible communication. Membership patients have secure messaging options for ongoing support between visits. LDN candidates include conditions like fibromyalgia, autoimmune diseases, and chronic pain syndromes. MCAS is considered an immune disorder from cumulative impacts.